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ZUSAMMENFASSUNG 
Borna Disease Virus (BDV) ist ein Vertreter der Bornaviridae in der Ordnung 
Mononegavirales (MNV). Unter denjenigen Viren dieser Ordnung, die Tiere infizieren, ist 
es bezüglich seiner Replikation und Transkription im Nukleus, einzigartig. BDV ist nicht 
zytolytisch, strikt neurotrop und verursacht Erkrankungen des zentralen Nervensystems 
(ZNS) bei einer großen Anzahl von Vertebraten, insbesondere beim Pferd.  
Der aktive BDV Polymerase Komplex besteht wie bei allen MNVs, aus dem 
Nukleoprotein N, dem Phosphoprotein P und der Polymerase L. Bei BDV ist daran 
außerdem noch das Protein X beteiligt. 
BVD N bildet Homotetramere und assoziiert nicht, wie im Gegensatz zu Nukleoproteinen 
anderer MNVs, mit zellulärer RNA. Jedes N Protomer besteht aus zwei helikalen 
Domänen und kurzen N- und C—terminalen Fortsätzen, mit deren Hilfe das N Tetramer 
stabilisiert wird. 
Es war jedoch nicht klar, wie BDV N mit der viralen RNA interagiert, obwohl die starke 
strukturelle Ähnlichkeit mit den Nukleoproteinen der Rhabdoviren auf vergleichbare 
RNA Interaktions-Modi hinwiesen. 
BDV-P spielt durch Interaktionen mit X, N, L und sich selbst eine essentielle Rolle beim 
Aufbau und der Regulierung des Polymerase-Komplexes, wobei die Oligomerisierung 
ähnlich wie bei anderen MNVs, für die Bildung eines aktiven Polymerase-Komplexes 
notwendig ist. 
P benötigt einen intakten C-terminus zur Interaktion mit dem Nukleoprotein N und 
kontaktiert möglicherweise zwei unterschiedliche Stellen auf N. Phosphoproteine von 
Rhabdoviren und Sendai Virus enthalten jeweils zwei unterschiedliche Bindestellen für 
N. Über die eine wird die Bindung des Nukleoproteins an unspezifische RNA verhindert, 
über die andere binden die Phosphoproteine an N-RNA Komplexe und vermitteln so die 
Ausbildung eines aktiven Polymerase Komplexes. Interessanterweise benötigt das 
Nukleoprotein von BDV das Phosphoprotein nicht, um die Interaktion mit unspezifischer 
RNA zu verhindern, da das Nukleoprotein spontan Tetramere ausbildet, ohne dabei RNA 
zu komplexieren, was eine Ausnahme unter den Mononegavirales darstellt. 
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Das Ziel meiner Untersuchungen war es, die Wechselwirkungen zwischen dem Nukleo- 
und dem Phosphoprotein, und dem Nukleoprotein und der viralen RNA mithilfe von 
biochemischen, biophysikalischen und strukturaufklärenden Methoden aufzuklären.  
Obwohl es nicht gelang, röntgenkristallographische Daten, weder von N-P, noch N-RNA 
Komplexen zu erhalten, konnte gezeigt werden dass P‘, eine N-terminal verkürzte und in 
BDV infizierten Zellen vorkommende Isoform des Phosphoproteins, zu Tetrameren 
oligomerisiert. Es interagiert mit N und formt mit diesem Heterooktamere, wobei die 
letzten 5 C-terminalen Aminosäurereste zur stabilen Komplexbildung benötigt werden. 
Das tetramerische Nukleoprotein wird in Anwesenheit von BDV genomischer 5’ RNA 
destabilisiert, was zu N-RNA Polymeren führt. Solche N-RNA Polymere, werden auch in 
Anwesenheit von P‘ gebildet. Elektronenmikroskopische Analysen der N-RNA und N-P‘-
RNA Komplexe zeigen große “offene” Ring- und Stäbchenartige Strukturen. Die RNA 
innerhalb dieser Strukturen bleibt dabei ungeschützt und zugänglich für RNase. Beim 
enzymatischen Abbau der RNA bleiben die N oder N-P‘ Polymere jedoch intakt, was die 
Vermutung zulässt, dass die Polymere nicht alleine durch die RNA stabilisiert werden. 
Interaktionen zwischen N und der viralen RNA werden durch Erkennung basischer 
Aminosäurereste im Inneren einer Spalte im Nukleoprotein vermittelt. 
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SUMMARY 
Borna disease virus (BDV) is the only representative of the Bornaviridae in the order 
Mononegavirales. It is unique among the animal viruses of this order with respect to its 
transcription and replication in the nucleus, which provides access to the splicing 
machinery. BDV is noncytolytic, highly neurotropic and causes diseases of the central 
nervous system (CNS) in a wide range of vertebrates. As in other Mononegavirales, the 
BDV polymerase complex or ribonucleoprotein complex, consists of the nucleoprotein N, 
the phosphoprotein P, the polymerase L and viral genomic RNA. In the case of BDV 
another protein is involved, termed protein X.  
BVD N forms a homotetramer and does not spontaneously interact with cellular RNA. 
Each protomer consists of two helical domains and N- and C-terminal extensions, 
involved in domain exchange and tetramer stabilization. 
An open question remained how BVD N interacts with RNA, although overall structural 
similarities with nucleoproteins from rhabdoviruses and vesiculoviruses suggested 
similar modes of RNA interaction.  
Protein P plays an essential role in assembly and regulation of the polymerase complex 
via interactions with X, N, L and itself. Oligomerization of P is required for the formation 
of an active polymerase complex, similar to other negative strand RNA polymerase 
complexes.  
P requires an intact C-terminus for N interaction and may contact two different sites on 
N. Phosphoproteins from Rhabdoviruses and Sendai virus contain two different binding 
sites for N, one to keep N soluble and free from unspecific RNA and the other to bind to 
N-RNA complexes forming the polymerase complex together with the polymerase L. 
However, BVD N does not require P binding to prevent non-specific RNA interaction, 
since BDV N oligomerizes spontaneously into tetramers that do not complex RNA, thus 
the precise role of N-P interaction in the absence of RNA is not known.  
The aim of our study was to understand the interaction between the BDV nucleo- and 
the phosphoprotein as well as the nucleoprotein and the viral RNA. Even though, no 
conclusive data were obtained upon crystallographic approaches, concerning N in 
complex with different truncated P-constructs and BDV genomic RNA, we present data 
about N-P and N-RNA interactions. 
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I show that P’, an N-terminally truncated isoform of the phosphoprotein, present in BDV 
infected cells, oligomerizes into tetramers. The tetrameric P’ interacts with BDV-N, thus 
forming hetero-octamers. The P’-N interaction requires five C-terminal amino acids of P’ 
to form a stable complex with a kD of 1.66 μM.  
Tetrameric N is destabilized in the presence of 5’ genomic BDV RNA, which leads to the 
formation of N-RNA polymers. Similar N-RNA polymers are formed in the presence of P’, 
leading to P’-N-RNA polymers. Electron microscopy analyses of N-RNA and N-P’-RNA 
complexes revealed large “open” ring-like and string-like assemblies with the RNA 
exposed and accessible for degradation. The N or N-P polymers remain intact after RNA 
degradation indicating that polymerization is not mainly stabilized by RNA interaction. 
The N-RNA interaction is mediated via recognition of basic residues within the cleft of 
the N-and C-terminal domains similar to the observed nucleoprotein-RNA recognition of 
other negative strand-RNA viruses.  
In conclusion, these data provide insight on the molecular interactions between the viral 
RNA and the nucleo- and phosphoprotein of the BDV ribonucleoprotein complex. 
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1  INTRODUCTION 
1.1  GENERAL INTRODUCTION 
1.1.1  NEGATIVE-SENSE RNA VIRUSES 
Negative-sense RNA viruses are enveloped viruses with a single-strand RNA genome in 
negative orientation. Their genomic RNA is either segmented or monopartite. Those 
representatives with a monopartite RNA genome are summarized within the order 
Mononegavirales (MNV) and are sub-divided into four families: Rhabdoviridae, 
Paramyxoviridae, Filoviridae and Bornaviridae. Their genes are arranged in a similar 
order on the genome and flanked by untranslated regions (UTRs) at the 5’ and 3’ 
termini, termed trailer and leader sequences, respectively. These regions contain 
promoter sequences within inverted terminal repeats (ITRs).  
MNVs are different in size and morphology (Figure 1) and infect a large spectrum of 
hosts, like plants, invertebrates and mammals.  
 
Figure 1: Electronmicroscopy images of Mononegavirales virus particles 
a) Ebola virus, Filoviridae (ICTVdB - Picture Gallery) 
b) Hemagglutinating virus of Japan, Paramyxoviridae (Kohno et al., 1999) 
c) Borna disease virus, Bornaviridae (Kohno et al., 1999) 
d) Vesiular stomatitis virus, Rhabdoviridae (ICTVdB - Picture Gallery) 
 
In non-segmented negative-sense RNA viruses, the active transcription and replication 
complex, called ribonucleoprotein (RNP) complex (Szilágyi &  Uryvayev, 1973; Murphy &  
Lazzarini, 1974) is composed of the viral RNA, the nucleoprotein N, the phosphoprotein 
P and the viral polymerase L (Emerson &  Wagner, 1972; Emerson &  Yu, 1975; Pattnaik 
et al., 1992). The major RNP component is N, which encapsidates the viral genome, thus 
forming N-RNA complexes to serve as a template for L (Emerson &  Wagner, 1972). 
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Because L cannot bind directly to N-RNA complexes, it is dependent on P, the 
polymerase cofactor (Portner &  Murti, 1986; Horikami &  Moyer, 1995). P tethers the 
polymerase towards the N-RNA complexes, stabilizes the RNP complex and serves as a 
scaffold for L (Mellon &  Emerson, 1978; Emerson &  Schubert, 1987; Curran, 1998). 
 
1.1.2  BORNA DISEASE HISTORY  
Borna disease obtained its name from the Saxon city of Borna, where in1885 a large 
number of horses from a cavalry regiment died from a fatal neurological disease. The 
disease has been described as Hitzige Kopfkrankheit or Enzootische Gehirn-
Rückenmarksentzündung der Pferde. Due to the major outbreaks around Borna and the 
tremendous losses of horses in this region, the disease was finally termed Bornasche 
Krankheit (Borna disease, BD).  
 
Figure 2: BDV-protein accumulation: Joest- Degen bodies 
a) Drawings of Joest-Degen bodies as seen by Ernst Joest in ganglion cells of horses with Borna disease 
(Joest, 1911). b) Inset: Joest Degen bodies (red) in multiple neurons of a BDV infected shrew. The scale bar 
indicates 100nm, (Hilbe et al., 2006). 
 
In 1909 Joest and Degen discovered the acidophilic inclusion bodies in the nuclei of 
infected horse ganglion cells, characteristic for Borna disease (Figure 2) (Joest &  Degen, 
1909; Joest, 1911). The causative agent of Borna disease was later attributed to a virus 
(Borna disease virus, BDV) by Wilhelm Zwick, since ultrafiltrated brain homogenates 
from infected horses caused BD in laboratory animals (Zwick &  Seifried, 1925; Zwick et 
al., 1926).  
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In 1994 the complete genome sequence of BDV has been discovered and the virus was 
finally classified as the prototype member of the family Bornaviridae in the order 
Mononegavirales (Cubitt et al., 1994). 
 
1.2  BORNA DISEASE VIRUS 
BDV is noncytolytic, highly neurotropic and leads to persistent infections in cell culture. 
It causes diseases (mostly meningoencephalitis and encephalomyelitis) of the central 
nervous system (CNS) mainly in horses and sheep. Also other animals such as cats, dogs, 
cattle and donkeys are susceptible to natural infection with BDV (Rott &  Becht, 1995; 
Ludwig &  Bode, 2000; Staeheli et al., 2000; Richt &  Rott, 2001). 
Recently, two new BDV strains have been discovered in psittacine birds with 
proventricular dilatation disease, a fatal inflammatory central, autonomic, and 
peripheral nervous system disease (Honkavuori et al., 2008). Experimental BDV 
infections were successful in rodents, non-human primates and chickens (Narayan et al., 
1983, Hallensleben, 1998 #5, Krey, 1979 #232; Lipkin &  Briese, 2007). It has also been 
proposed that BDV may infect humans and causes a variety of neuropsychiatric 
disorders, but this idea is still discussed controversially (Richt &  Rott, 2001; Dürrwald et 
al., 2007). 
The reservoir host is unknown so far, although the bicolored white-toothed shrew, 
Crocidura leucodon, has been considered as a potential virus reservoir due to BD cases in 
an area in Switzerland (Hilbe et al., 2006).  
BD occurs usually sporadically in horse populations and only limited to certain areas in 
middle- and southern- Germany, as well as Switzerland and Austria. Less than 100 BD 
cases occur per year. However, antibodies against BDV can be found in horses all over 
Europe, North America, Asia and Africa, assuming a wide spread of BDV or related 
viruses.  
The incubation time ranges from two weeks to several months and the symptoms of 
naturally occurring BDV infections are variable. Some of the infected animals are devoid 
of any symptoms. In other cases, unspecific symptoms as fever, asitia, nervous or 
lethargic behaviour and constipation may appear. With further progression of acute 
infection, classical Borna disease is manifesting. This is a result of the destruction of the 
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CNS through the T-cell mediated immune response of the host. This is manifested by 
significant drawback of motor function coordination and behavioural disorders, such as 
depression, excitement and somnolence. The course of disease lasts 3 to 20 days and 
ends usually fatal (Richt et al., 2006). The animals die from exhaustion, aspiratory 
pneumonia and by decubitus-caused sepsis. Surviving horses often show sensory and 
motor damage (Becht &  Richt, 1996). Efficient therapy or vaccines are currently not 
available. 
 
1.2.1  BDV MORPHOLOGY 
BDV particles are spherical, enveloped, and between 50 and 190nm in diameter; 
however, it is assumed that particles smaller than 80 nm are defective or immature 
particles, since infective particles did not pass through a filter with less than 80nm pore 
size (Danner &  Mayr, 1979; Zimmermann et al., 1994; Kohno et al., 1999).  
 
Figure 3: Schematic drawing of BDV particle 
 
The envelope contains spikes of ~7 nm in length. A crescent-shaped inner structure is 
visible in EM images of negatively stained ultrathin sections of BDV infected MDCK cells 
(Figure 1c), embedded in epoxy-resin. This structure had a diameter of ~4nm and was 
supposed to constitute the nucleocapsid. Structures, slightly larger in mean size have 
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also been observed, assuming that other BDV proteins like the phosphoprotein and the 
polymerase were attached (Kohno et al., 1999). Figure 3 shows a schematic drawing of 
the BDV particle.  
 
1.2.2  PATHOGENESIS 
Studies on experimentally infected animals strongly contributed to the understanding of 
the pathogenesis. This is best studied in rats, since the pathology found after 
intracerebral infection of Lewis rats is comparable to the immunopathology found in 
naturally infected horses and sheep (Richt et al., 2006). 
Infection in adult rats is achieved by any route that allows virus-access to nerve 
terminals (by olfactory, ophthalmic, or intraperitoneal inoculation), which ultimately 
results in CNS infection and classic disease. Transmission may occur via direct contact 
with body fluids, such as saliva, nasal mucous, tears and urine or by exposure to 
contaminated objects (Kishi et al., 2002; Richt et al., 2006). 
After entering the nervous system, BDV migrates along the axons of the olfactory system 
to the brain. There, it replicates in neurons and glial cells, primarily in the limbic system 
and spreads over time throughout the CNS and further to the peripheral nervous 
system. Axonal transport shields BDV from the humoral immune response, explaining 
the lack of neutralizing antibodies until late in infection. Nevertheless, they seem to 
control virus tropism and are able to prevent the spread of virus from peripheral 
infection sites to the CNS (Furrer et al., 2001; Stitz et al., 2002). 
BDV infected adult rats develop an encephalomyelitis in which infiltrating lesions can be 
found mainly in the cortex and in the hippocampus in areas where the virus is present. 
The symptoms are not a result of viral replication, but of a T-cell mediated 
immunopathologic reaction (Richt et al., 1992; Stitz et al., 1993). Thereby CD8+ T cells 
significantly contribute to the destruction of virus-infected brain cells in vivo by 
triggering their lysis, which leads to behavioural disorder and usually ends fatal (Stitz et 
al., 2002). 
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1.2.3  THE BDV LIFE CYCLE 
VIRUS ENTRY. BDV G (GP-N and GP-C), the surface glycoprotein, plays a pivotal role in 
receptor recognition and cell entry (Gonzalez-Dunia et al., 1997) (Figure 4). BDV enters 
the cells via receptor-mediated endocytosis with the aid of an unknown cellular receptor 
(Gonzalez-Dunia et al., 1998; Perez et al., 2001). After intracranial inoculation BDV 
replicates primarily in neurons, implying that this receptor has a restricted expression 
pattern in vivo.  
 
Figure 4: Replication cycle of BDV adapted and modified from (de la Torre, 2006) 
 
While BDV GP-N was found to be competent for receptor recognition and virus entry, 
GP-C seems to be responsible for the pH-dependent fusion event in the endosome, 
required to release the viral ribonucleoprotein (RNP) into the cytoplasm of infected cells 
(Gonzalez-Dunia et al., 1998). No data are available yet, concerning intracellular 
trafficking of the nucleocapsid after membrane fusion.  
REPLICATION AND TRANSCRIPTION. BDV RNA replication and gene transcription occurs in the 
nucleus, which requires active nucleocytoplasmic transport of viral RNA and proteins. 
Based on the nuclear localization sites (NLS) and nuclear export signals (NES), located on 
N, P, and X, several hypotheses have been brought up regarding nucleocytoplasmic 
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shuttling of BDV nucleocapsid components, but no conclusive data are available 
(Kobayashi et al., 2001; Yanai et al., 2006).  
 
Figure 5: Sequential electron microscope images of the budding process in induced MDCK/BDV cells.  
The spiked membrane area (arrow in panel a) becomes an extracellular particle (d). (b and c)are 
intermediate stages of the budding. Scale bar, 100 nm. Images were taken from (Kohno et al., 1999) 
 
PACKAGING AND EGRESS. Assembly of mature viral particles requires nuclear export of 
newly synthesized viral RNPs and their association with viral surface glycoproteins. The 
subcellular location and mechanisms underlying BDV particle formation have not been 
determined and no packaging signals are defined yet. There is evidence that cell-to-cell 
propagation of BDV might proceed in absence of the formation of mature viral particles. 
This process may be mediated by the BDV RNP complex (de la Torre, 2006). Budding of 
virion structures was observed from spike-containing membrane regions in n-butyrate 
treated, persistently infected cultured cells (Pauli &  Ludwig, 1985; Kohno et al., 1999) 
(Figure 5). Late in infection, BDV is detected in many tissues and organs as a 
consequence of its centrifugal spread through the axoplasm of peripheral nerve tissues. 
However, the underlying mechanisms remain unknown so far. 
 
1.2.4  GENOME ORGANIZATION 
The BDV genome has a size of 8.9 kB and is hence the smallest among the genomes of 
NNS viruses. It shows the typical organization of the Mononegavirales; six major partially 
overlapping open reading frames (ORFs) are contained within the sequence (Cubitt et 
al., 1994; Briese et al., 1995; Schneemann et al., 1995; Wehner et al., 1997; de la Torre, 
2002) (Figure 6). Due to the biochemical properties and functions of the encoded 
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proteins, they were assigned as the counterparts of N, P, M, G and L proteins of the 
other NNS viruses (Perez et al., 2003; Schneider et al., 2003; Perez &  de la Torre, 2005; 
Schneider, 2005). Another typical feature is the existence of short untranslated regions 
(UTR) at the 3’- and 5’-ends of the genome which possess promoter elements for 
transcription and replication. However, the BDV UTRs appear to be heterogeneous 
(Briese et al., 1994; Cubitt &  de la Torre, 1994; Pleschka et al., 2001; Rosario et al., 
2005), which is in contrast to the UTRs of the other NNS viruses, where these sequences 
of up to 20 nucleotides are perfectly complementary to each other. 
The genome is divided into three transcription units (I-III) with three different 
transcription initiation sites (S1-S3, Figure 7) and four polyadenylation 
signals/termination sites (T1-T4) (Schneemann et al., 1994), which can be partially read 
through by the polymerase L, leading to the synthesis of a wider variety of transcripts 
and the generation of a template RNA (+RNA or antigenome) for genome replication.  
 
Figure 6: Open reading frames of BDV 
ORFs from 3’ to 5’: Nucleoprotein (N), protein X (X), partially overlapping with the ORF of the 
phosphoprotein (P), matrixprotein (M), polymerase (L) and the glycoprotein (G) ORF, which partially 
overlaps with the ORFs of M and L 
 
 
1.2.5  TRANSCRIPTION AND REPLICATION 
As mentioned above, Borna disease virus is the only known animal NNS virus with a 
nuclear phase (Briese et al., 1992). The genomic RNA, encapsidated by the nucleoprotein 
N, serves as a template for the associated polymerase complex components L and P like 
in other negative-strand RNA viruses. Recombinant minigenome systems verified that N, 
P, and L proteins are essential and sufficient for BDV transcription and replication (Perez 
&  de la Torre, 2005), although there is recent evidence that the BDV protein X is 
required too for efficient replication of BDV (Poenisch et al., 2008).  
Transcription of the genome is presumably starting at position +44 of the genomic 3’ 
end (Figure 7) resulting in a transcription gradient, which however, is less pronounced 
than in most other Mononegavirales (Schneider, 2005). All mRNAs are polyadenylated 
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and contain a 5’-cap structure. The nucleoprotein (N) is the only protein translated from 
a monocistronic mRNA, emerging from transcription unit I. Read-through of the 
polymerase from S1 leads to a 1.9 kB RNA, including the ORFs of N, P and X. Unlike 
previously assumed, it is a fully functional mRNA, serving as an additional template for 
the three proteins and is suggested to serve a regulatory function in viral gene 
expression (Schneemann et al., 1994; Poenisch et al., 2008).  
A bicistronic mRNA is produced from transcription unit II, starting at S2 and terminated 
at T2, encoding accessory protein X and the phosphoprotein P (Figure 7), (Schneider, 
2005). The ORFs of these two proteins partially overlap in a different frame (de la Torre, 
2006). Polymerase read-through at T2 occurs rarely till T3, the synthesized transcript is 
suggested to serve as an additional template for X and P translation No evidence exists 
of splicing to eliminate the first AUG codon initiating translation of X. Thus, it is likely 
that P is expressed through a leaky scanning mechanism. 
Splicing occurs exclusively in transcripts from transcription unit III (Cubitt et al., 1994; 
Schneider et al., 1994; Tomonaga et al., 2000). All primary transcripts of transcription 
unit III (S3) contain the overlapping ORFs of M and G. Introns are within the coding 
regions of M (Intron 1) and G (Intron 2). M is translated from all transcripts containing 
Intron 1, whereas splicing of this intron is necessary for efficient translation of G. Splicing 
of Intron 2 from the primary transcript terminated at T4 creates a large ORF encoding L 
(p190), which is only translated efficiently if Intron 1 is removed. Variable splicing of 
these introns thus enables BDV to regulate the expression of M, G and L. It is suggested 
that the viral polymerase complex influences splicing events because splicing is unlike in 
cDNA derived BDV mRNAs rather inefficient in BDV infected cells (Jehle et al., 2000). 
BDV persistence requires a stringent regulation of viral replication, but little is known so 
far about the respective mechanisms. The 5’ and 3’ UTRs of NNS viruses contain 
promoter sequences which constitute inverted terminal repeats (ITR) with a high degree 
of sequence complementarity, which has the potential to form a panhandle structure 
with matching 5’ and 3’ termini. Such panhandle structures were found to be important 
regulatory elements of replication for members of the Orthomyxoviridae and 
Bunyaviridae families.  
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Figure 7: Genomic organization and transcription map of BDV. 
N, nucleoprotein p38/p40N; X, protein X; P, phosphoprotein p24/p16; M, matrix protein; G, envelope 
glycoprotein; L, polymerase protein; S1-S3, transcription initiation sites; T1-T4 
polyadenylation/termination sites. Positions of the introns are indicated by 1 and 2. 
 
In the case of MNVs, it is unclear whether a panhandle structure is formed during viral 
replication, or whether the terminal complementarity of the genome simply reflects 
similar sequence requirements of the genomic and antigenomic promoters (Schneider, 
2005). Analysis of genomic termini in acute and persistent BDV infection indicated the 
accumulation of genomes with truncated 3’ and 5’ termini in persistent cultures (Rosario 
et al., 2005). Rescue of infectious recombinant BDV constructs demonstrated that 
trimming of the genomic 5’-terminus is an intrinsic feature of the BDV polymerase 
complex (Schneider et al., 2005). In this system, genomic trimming generated termini 
with a recessed 5’ end, leads to a strongly attenuated replication phenotype. The 
transcriptional activity, however, was not affected by the noncomplementary termini. 
This is compatible with high levels of antigen expression accompanied by extremely low 
levels of infectious virus, characteristic for persistent BDV infection. 
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1.2.6  BDV PROTEINS 
The BDV genome encodes six proteins: nucleoprotein (N), phosphoprotein (P), matrix 
protein (M), glycoprotein (G), polymerase (L) and accessory protein X. The virus is made 
up of two major structural components: a ribonucleoprotein (RNP) core (Figure 8) and a 
surrounding envelope. In the RNP, genomic RNA is encased by the nucleoprotein. 
Furthermore, two other viral proteins, P and L, are associated and form the RNP 
complex.  The glycoprotein and the host-cell derived membrane it is embedded in, 
constitute the viral envelope. The M protein is associated with both the envelope and 
the RNP and forms the inner lining of the virus (see 1.2.1 and figure 3). Protein X is 
abundantly present in infected cells and is supposed to serve an essential role in the 
formation of an active polymerase complex. 
 
Figure 8: Schematic drawing of the BDV ribonucleoprotein complex 
The viral RNA is encapsidated by the nucleoprotein (yellow). The phosphoprotein (green) serves as a 
mediator between the polymerase L (blue) and the N-RNA. The singular components  are indicated in the 
picture. 
 
X PROTEIN 
Similar to the C-protein of VSV, BDV X is encoded from a shared ORF with BDV P (see 
Figure 6 and 7). It is with 87 amino acid residues (10 kDa) the smallest BDV protein 
(Wehner et al., 1997). Protein X exhibits various functions in the BDV replication cycle; 
recently, it has been shown to play an essential role during the viral multiplication cycle 
by stimulating the assembly of an active polymerase complex. (Poenisch et al., 2004; 
Poenisch et al., 2007; Poenisch et al., 2008). Furthermore it is suggested that regulation 
of X expression contributes to viral fitness (Poenisch et al., 2009).However, very low 
levels of X have been detected (X:P ratio was 1:300) in purified BDV stocks and X has 
thus been proposed as a non- structural BDV protein (Schwardt et al., 2005). 
Protein X occurs in both nuclear and cytoplasmic compartments. Nuclear localization of 
X may be achieved via its interaction with P. On the other hand, the P interaction site is 
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located at the N-terminus (S3DLRLTLLELVRRL16) which partially overlaps with an unusual 
importin-binding motif (R6LTLLELVRRNGN19) for nuclear transport (Malik et al., 2000; 
Wolff et al., 2000; Wolff et al., 2002).  
The abundance of NLS and NES of BDV proteins makes it however difficult to attribute 
these sites to particular events during viral multiplication. 
 
 
THE VIRAL ENVELOPE  
GLYCOPROTEIN 
BDV cell entry follows a receptor-mediated endocytosis pathway which is initiated by 
the recognition of an as-yet-unidentified receptor on the cell surface by the viral 
glycoprotein G (Figure 3 and 4).  
The primary translation product of BDV G is a 56 kDa polypeptide, but posttranslational 
modification by N-glycosylation with high-mannose oligosaccharides of the complex 
type, results in a 94 kDa protein (gp94) (Schneider et al., 1997; Richt et al., 1998; 
Kiermayer et al., 2002). Therefore G might play a critical role in virus persistence by 
protection of antigenic epitopes via decoration with host identical N-glycans (Eickmann 
et al., 2005).  
Only the cleaved form of G is incorporated into the virus particles (Eickmann et al., 
2005). This is achieved by the cellular protease furin which cleaves BDV G into an N- (GP-
N, 51 kDa) and a C-terminal fragment (GP-C, 43 kDa) (Richt et al., 1998; Kiermayer et al., 
2002). While GP-N is sufficient for receptor recognition and virus entry, GP-C may be 
involved in fusion events after internalization of the virus by endocytosis (Gonzalez-
Dunia et al., 1998; Perez et al., 2001).  
 
MATRIXPROTEIN (M) 
The matrix protein M of Borna disease virus (BDV) is a constituent of the viral envelope 
covering the inner leaflet of the lipid bilayer. It has a size of ~16 kDa (142aa) and is 
therefore the smallest among the NNS virus matrixproteins. BDV M oligomerizes in vivo 
and in vitro, whereas the most stable structural unit is a tetramer (Figure 9). The 
tetramers in turn can form 2D lattice-like structures, supporting the view that M 
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constitutes the major driving force for the formation of viral particles (Stoyloff et al., 
1997; Kraus et al., 2005).  
The recently determined crystal structure of recombinant BDV M (Figure 9a-c) revealed 
a mainly basic surface charge on one face of the structure, indicating membrane 
interaction properties (Figure 9a) (Neumann et al., 2009).  
 
Figure 9: Membrane- and RNA-binding properties of BDV M 
a) and b): Surface properties of the putative membrane-binding face of the BDV-M tetramer. a) The 
electrostatic surface potential reveals this face to be highly basic (areas colored in white, red, and blue 
denote neutral, negative and positive potentials, respectively). b) Bottom view of a) rotated 180° around 
the y-axis. Schematic depiction of the possible binding mode of ssRNA according to (Neumann et al., 
2009). A distinctive basic patch along the tetramer diagonals could accommodate the polyphosphate 
backbone (yellow arrows), such that an incoming chain (3’-end bottom left) ends with the observed bound 
nucleotide (center). Assuming a specificity for cytidine/uridine, there are 3 possible exit routes for the 5’-
end: (i) at the top left, with 1 pyrimidine base bound near the tetramer axis; (ii) at the top right, with 2 nt; 
and (iii) at the bottom right, with 3 central bases contributing to specificity. It is not possible to distinguish 
between them because of the 4-fold crystallographic symmetry. Figures from a) and b) were taken from 
(Neumann et al., 2009). c) Ribbon diagram of the BDV M tetramer, bound to RNA. PDB ID: 3F1J d) Ribbon 
diagram of the Ebola virus VP40 N-terminus octamer bound to RNA. PDB ID: 1H2C. Proteins are depicted 
in white, RNA in color; ribbon diagrams were generated with Pymol 0.99. 
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The opposite face however, was shown to be associated with RNA, as demonstrated for 
the N-terminus of Ebola virus VP40 (Figure 9d) and the M protein of respiratory syncytial 
virus(Gomis-Rüth et al., 2003; Rodríguez et al., 2004). Two S-shaped basic patches, 
running diagonally over the surface (Figure 9b), may accommodate the phosphate 
backbone of the RNA (Figure 9b, c). The only similarity between known structures of 
MNV M proteins is exhibited by the BDV M monomer and the N- and C-terminal 
domains of VP 40 of Ebola virus. The RNA binding properties of M suggest that it could 
play a role in ribonucleoprotein (RNP) complex formation or nucleocapsid condensation 
as shown for VSV M (Newcomb &  Brown, 1981; Neumann et al., 2009). Besides, BDV M 
co-localizes with N, P and X in the nuclei and cytoplasms of persistently infected cells 
and binds to P in vitro. This implies that M is an integral component of the viral RNP 
(Chase et al., 2007).  
PROTEINS OF THE RIBONUCLEOPROTEIN COMPLEX 
PHOSPHOPROTEIN (P) 
The BDV phosphoprotein (24 kDa, 201 aa) plays a pivotal role in the BDV life cycle. It 
influences the cellular immune response and signaling pathways through interaction 
with cellular factors. Moreover, P acts as a mediator for the assembly and regulation of 
the polymerase complex via interactions with X, N, L and itself (Schwemmle et al., 1998; 
Walker et al., 2000; Schneider et al., 2004). Due to replication and transcription of BDV 
in the nucleus, components of the polymerase complex are shuttling between nucleus 
and cytoplasm. Therefore, P contains two NLS and one NES (Figure 10). Although it is not 
clear to which extent P contributes to nuclear and cytoplasmic trafficking of BDV 
components, since N and X exhibit such properties as well (Shoya et al., 1998; 
Schwemmle et al., 1999; Yanai et al., 2006). 
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Figure 10: Schematic representation of the BDV-P protein.  
The long (P) and the short (P’) isoform of the BDV phosphoprotein are represented by green bars. The two 
independent nuclear localization signals (NLS) are indicated by grey boxes and nuclear export signals (NES) 
in turquoise. The self, N, L, M and X boxes indicate the domains responsible for the interaction of P with 
the respective BDV protein. Phosphorylation sites are indicated by red (PKCε sites) and blue (CKII sites) 
sticks). Positions of amino acids defining the boundaries of the NLS, the coiled coil motif (vertical dashed 
line) and the various interaction domains are indicated. 
 
P activity as a co-factor of L is negatively regulated by phosphorylation at Serines (Figure 
10) (Schwemmle et al., 1997; Schmid et al., 2007). Phosphorylation is predominantly 
attained by protein kinase Cε (PKCε) (not present in all strains) and- to a lesser extent- 
by Casein kinase II (CKII) (Schwemmle et al., 1997). Mutational analysis of the 
phosphorylation sites revealed that aspartate substitutions (to mimic phosphorylation) 
at CKII sites inhibited the polymerase supporting activity of P. Aspartate substitutions at 
PKCε sites however, showed no inhibition (Schmid et al., 2007).  
BDV P oligomerization is required for the formation of an active polymerase complex, 
similar to other negative-strand RNA polymerase complexes (Curran, 1998; Choudhary 
et al., 2002; Schneider et al., 2004; Möller et al., 2005; Albertini et al., 2008). It is likely 
achieved via a predicted coiled coil motif that partially overlaps with the interaction site 
of L (Schneider et al., 2004; Schneider, 2005).  
Two isoforms of BDV-P have been detected in infected cells, resulting from alternative 
usage of in-frame AUG-initiation codons. The short isoform P’ (16 kDa, aa 56-201; Figure 
10) lacks the N-terminal 55 aa of full-length P, and one of two independent NLS (Figure 
10). Due to its nuclear localization and the ability to interact with N, L, X and itself (P’ 
and P) in vivo, it was proposed to play an important role during replication and 
transcription in BDV infected cells (Kobayashi et al., 2000). However, it does not seem to 
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support reporter-gene expression in a viral minireplicon system (Kobayashi et al., 2000; 
Schneider et al., 2004).  
 
NUCLEOPROTEIN (N) 
Viral nucleoproteins are the major components of the RNP; they encapsidate the viral 
genome, thus forming N-RNA complexes to serve as a template for the viral polymerase 
L (Horikami et al., 1992). However, direct BDV nucleoprotein-RNA interaction has 
previously not been demonstrated. BVD N consists of 371 aa and forms a planar 
homotetramer in the crystal structure and in solution (Figure 11). As it is able to interact 
with P but not with L, it exhibits the typical characteristics of NNS virus nucleoproteins, 
which are dependent on P mediation for the formation of an active polymerase complex 
as a prerequisite for successful viral replication and transcription (Horikami et al., 1992; 
Schneider et al., 2004).  
Furthermore, the protein exhibits nucleo-cytoplasmic shuttling activity via a nuclear 
localization signal (NLS; 3PKRRLVDDA11) and a nuclear export signal (NES; 
128LTELEISSIFSHCC141), which is consistent with the requirement of RNA transport into 
and out of the nucleus for replication and transcription (Figure 11c) (Kobayashi et al., 
1998; Kobayashi et al., 2001). In contrast to other MNVs, BDV N-P interaction is 
supposed to be achieved by two motifs located at the N-terminus of N (K56- Y100 and L131-
I158, Figure 11c) (Berg et al., 1998). The first motif is solvent exposed in the N tetramer 
structure, whereas the second motif however is entirely inaccessible to solvent and 
deeply buried within the hydrophobic core of the N-terminal domain, ruling out any 
possible involvement in P binding (Rudolph et al., 2003). 
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Figure 11: The BDV Nucleoprotein 
a) Ribbon diagram of the nucleoprotein tetramer, top-view (on the N-terminaldomain). b) Bottom view (on the C-
terminal domain) of a), rotated 180° around the X-axis. Each N-protomer is depicted in a different colour. Ribbon 
diagrams were generated with Pymol 0.99. Protein Data Bank ID: 1PP1, by (Rudolph et al., 2003). c) Schematic 
representation of BDV N. Putative interaction sites with BDV P, NLS and NES are depicted in green, grey and blue 
respectively. 
 
RNA-DEPENDENT RNA POLYMERASE (L) 
The 1711 aa (190 kDa) BDV L protein is translated from a continuous ORF, fused after 
splicing of a short (6 nucleotides) to a large (5118 nucleotides) exon (Briese et al., 1994; 
Schneemann et al., 1994; Schneider et al., 1994). It interacts with the BDV 
phosphoprotein and is phosphorylated by cellular kinases (Walker et al., 2000; Schneider 
et al., 2003). Nuclear localization of L is accomplished either by an NLS motif 
(R844VVKLRIAP852) or by interaction with P (Walker et al., 2000; Walker &  Lipkin, 2002; 
Schneider et al., 2003). The interaction-site with P has not been mapped yet; despite 
sequence similarities among MNV L proteins, there is no consensus for P interaction 
(Chenik et al., 1998; Holmes &  Moyer, 2002). 
As mentioned above, BDV L harbours conserved domains and motives and is thus the 
only BDV protein, showing sequence similarities with other NNS viruses (Poch et al., 
1990; Tordo et al., 1992; de la Torre, 1994; Schneemann et al., 1995). The presence of 
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three RGD motifs in the C-terminal region and the exchange of a lysine residue against a 
serine in domain III of motif A -a highly conserved motif among ATP- or GTP-binding 
proteins, which interacts with one of the phosphate groups of nucleotides- makes BDV L 
unique. It is yet unknown if these features are directly linked to L functions or if they are 
matter of evolutionary signatures (de la Torre, 2006).  
 
NUCLEOPROTEIN-RNA INTERACTION 
Nucleoproteins of negative strand RNA viruses condense the viral RNA into helical 
structures (Figure 12a-c) and thus serve, together with the encapsidated RNA, as a 
template for the viral polymerase.  
However, the mode of RNA interaction and condensation differs from virus to virus. 
Nucleoproteins of many MNVs, such as Rhabdoviruses, Sendai and Marburg virus, 
interact spontaneously with RNA, albeit its origin is cellular or viral. To prevent N-
association with unspecific RNA, P acts as a chaperone by interaction with N (Fooks et 
al., 1993; Iseni et al., 1998; Yang et al., 1998; Schoehn et al., 2001; Mavrakis et al., 2002; 
Green &  Luo, 2006; Albertini et al., 2007). Yet, BDV N does not spontaneously interact 
with cellular RNA, but forms homooligomers in the crystal structure as well as in 
solution, as demonstrated for influenza virus nucleoproteins (Rudolph et al., 2003; Ye et 
al., 2006).  
 
 
Figure 12: Electron micrographs of negatively stained nucleoprotein–RNA complexes of nonsegmented 
negative-strand RNA viruses. 
a) Marburg virus N-RNA, recombinant from insect cells. b) Rabies virus N-RNA, virus isolate. c) Sendai virus 
N-RNA, virus isolate. The scale bar indicates 100nm for all three images. Images were taken and modified 
from (Mavrakis et al., 2002). 
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AIMS 
BDV holds a special position among animal Mononegavirales, regarding its replication 
and transcription in the nucleus of the infected cell. Furthermore its nucleoprotein N is, 
amongst others responsible for encapsidation of the viral genome and does not 
spontaneously interact with cellular RNA. Therefore, the encapsidation of RNA is not 
dependent on the phosphoprotein P, which acts as a “chaperone” regarding RNA 
packaging, as shown for the other members of this order. On the other hand, the BDV 
nucleoprotein shows overall structural similarities with N proteins of rabies and vesicular 
stomatitis virus.  
Those special features make BDV an interesting item to study, elaborating differences 
and similarities with other MNVs, concerning RNP complexes and their various roles 
within the viral replication cycle, in particular.  
The main goal of this work was to contribute to a better understanding of the structure 
and function of components of the BDV RNP complex, in particular the regulation of viral 
transcription and replication.  
Therefore, we used biochemical, biophysical and structural approaches to characterize 
different complexes, which are part of the BDV ribonucleoprotein complex: 
• Nucleoprotein- phosphoprotein 
• Nucleoprotein- RNA  
• Nucleoprotein-Phosphoprotein-RNA. 
Due to difficulties with the full-length phosphoprotein, the N-terminally truncated and 
isoform P’ has been used during almost all experiments. 
The following specific aims have been proposed at different stages during the work, in 
order to answer the subsequent questions: 
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Part 1 
Characterization and structural analysis of the BDV N-P interaction and 
oligomerization properties of N-P’ and P’. Does BDV N undergo significant 
conformational changes upon interaction with P/P’, possibly in order to render 
the RNA accessible for the viral polymerase L? Which is the stoichiometry of an 
N-P/P’ complex. How do N and P’ interact with each other, concerning 
interaction sites and affinity?  
Part 2  
Characterization and structural analysis of N-RNA and N-P’-RNA complexes and 
specificity of N-RNA complex-formation. Which are the similarities and 
differences between BDV N-RNA complexes and those of other MNVs? How does 
N recognize viral specific RNA and is the RNA protected upon interaction with N? 
Which amino acid residues are involved in N-RNA interaction? Does P interfere 
with the formation of N-RNA complexes or does it loosen a possibly tight N-RNA 
association to facilitate replication and transcription?  
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2  MATERIALS AND METHODS 
 
2.1  MATERIALS 
 
2.1.1  CHEMICALS AND REAGENTS 
2-Mercaptoethanol     Sigma, Lyon, F 
Acetic acid      Euromedex, Mundolsheim, F 
Acryl amide 30% Rotiphorese    Roth, Karlsruhe, D 
AccuGel 19:1 Acrylamide 40%   National Diagnostics, Atlanta, USA 
Agar-agar      Merck, Darmstadt, D 
Agarose      Biorad, Marnes-la-Coquette, F 
Ampicilline      Euromedex, Mundolsheim, F 
Anhydrotetracycline     IBA, Göttingen, D 
APS (Ammonium persulfate)       Euromedex, 
Mundolsheim, F 
ATP (Adenosine-triphosphate)   Fluka, Seelze, D 
Boric Acid      Sigma, Lyon, F 
Bromophenol blue     Biorad, Marnes-la-Coquette, F 
BSA (Bovine serum albumine)    Roche, Meylan, F 
Calcium Chloride (CaCl2)    Fluka, Seelze, D 
Carbenicilline      Euromedex, Mundolsheim, F 
Complete® EDTA free protease inhibor  Roche, Meylan, F 
Coomassie brilliant blue     Serva, Heidelberg, D 
G-250       Euromedex, Mundolsheim, F 
CTP (Cytosine-triphosphate)    Jena Bioscience, Jena, D 
D-Desthiobiotine     Sigma, Lyon, F 
DMSO       Sigma, Lyon, F 
DTT (Dithiotreitol)     Euromedex, Mundolsheim, F 
EDTA (ethylene diamine tetraacetic acid)  Euromedex, Mundolsheim, F 
EGS (ethylene glycol bis succinimidyl-succinate) Pierce, Brebières, F 
Ethanol      Fisher Scientific, Pittsburgh, 
USA 
Ethidium bromide     Euromedex, Mundolsheim, F 
Formaldehyde 37%     Sigma, Lyon, F 
Glutaraldehyde     Sigma, Lyon, F 
Glutathione      Euromedex, Mundolsheim, F 
Glycerol      Euromedex, Mundolsheim, F 
Glycine      Euromedex, Mundolsheim, F 
GTP (Guanosine-triphosphate)   Jena Bioscience, Jena, D 
HABA (2-(4-Hydroxyphenylazo)benzoeacid)  Sigma, Lyon, F 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid )    
       Euromedex, Mundolsheim, F 
Hydrochloric acid (HCl)    Carlo Erba Reactifs, Val de  
       Reuil, F 
IPTG (Isopropyl-ß-D-thiogalactopyranoside)  Euromedex, Mundolsheim, F 
Isopropanol      Fisher Scientific, Pittsburgh, 
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USA 
Potassium chloride (KCl)    Sigma, Lyon, F 
Luria Bertani Medium     AthenaES, Baltimore, UK 
Magnesium Chloride (MgCl2)    Sigma, Lyon, F 
Methylene blue     Roth, Karlsruhe, D 
PEG       Fluka, Seelze, D 
Phenol-Chloroform-Isoamyalcohol (25 :24 :1) MP Biomedicals, Illkirch,F 
SDS (Sodiumdodecylsulphate)   Serva, Heidelberg, D 
Sodium acetate (CH3COONa)    Fluka, Seelze, D 
Sodium Chloride (NaCl)    Euromedex, Mundolsheim, F 
Sodium Hydroxide (NaOH)    Carlo Erba Reactifs, Val de  
       Reuil, F 
Spermidine      Roth, Karlsruhe 
Streptomycine     Euromedex, Mundolsheim, F 
TEMED      Roth, Karlsruhe, D 
Tris Base      Euromedex, Mundolsheim, F 
Triton X      Roth, Karlsruhe, D 
Tween 20      Roth, Karlsruhe, D 
Urea ((NH2)2CO)     Euromedex, Mundolsheim, F 
UTP (Uracyl-triphosphate)    Fluka, Seelze, D 
Xylene Cyanol blue     Roth, Karlsruhe, D 
 
 
2.1.2  EQUIPMENT 
Aektaprime plus     GE Healthcare Europe, Saclay, F 
Aekta Purifier      GE Healthcare Europe, Saclay, F 
Biophotometer     Eppendorf, Hamburg, D 
Hoefer SemiPhor Transfer Unit   Hoefer Inc., San Francisco, USA  
Centrifuge 5424     Eppendorf, Hamburg, D 
Centrifuge 5804R     Eppendorf, Hamburg, D 
Concentrator Vivaspin 4 (10k MWO)   Sartorius, Göttingen, D 
Concentrator Vivaspin 15 (10k MWO)  Sartorius, Göttingen, D 
Slide-a-Lyzer Dialysis Cassette (3-12 MWO)  Pierce (Perbio Science), Brebières, F 
GeBAflex Dialysis Maxi kit (6-8 MWO)  GEBA, Kfar Hanagid, IL 
Dialysis bag      Spectrum, DG Breda, NL 
Minispin plus      Eppendorf, Hamburg, D 
Filters (45 and 22μm)     Dominique Dutscher, Brumath, F 
PCR Thermo Cycler     Biometra, Göttingen, D 
Electric Power supply     Biorad, Marnes-la-Coquette, F 
Protane Mini gel System    Biorad, Marnes-la-Coquette, F 
pH-meter Docu pH     Sartorius 
Research® Pipette (0.1-2.5µl)    Eppendorf, Hamburg, D 
Research® Pipette (0.5-10µl)    Eppendorf, Hamburg, D 
Research® Pipette (10-100µl)    Eppendorf, Hamburg, D 
Research® Pipette (20-200µl)    Eppendorf, Hamburg, D 
Research® Pipette (100-1000µl)   Eppendorf, Hamburg, D 
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Syringe (1,2,5,10,20 and 50ml)   Terumo Europe, Leuven, B 
Thermoblock      Falc, Treviglio, I 
 
 
2.1.3  KITS 
BugBuster      Novagen, Darmstadt, D 
DIG Northern starter kit    Roche, Meylan, F 
EndoFree Plasmid Mega Kit    Qiagen, Courtaboeuf, F 
HiSpeed Plasmid Maxi Kit    Qiagen, Courtaboeuf, F 
QIAquick gel extraction Kit    Qiagen, Courtaboeuf, F 
QIAquick PCR purification Kit    Qiagen, Courtaboeuf, F 
Wizard® plus Minipreps DNA purification Systems Promega, Charbonnieres, F 
Wizard® plus Midipreps DNA purification Systems Promega, Charbonnieres, F 
Wizard® plus Megapreps DNA purification Systems Promega, Charbonnieres, F 
SV Total RNA Isolation System   Promega, Charbonnieres, F 
Z-competent E.coli transformation buffer set ZymoResearch,  
 
 
2.1.4  COLUMNS AND RESINS 
Chelating Sepharose Fast Flow 
Glutathion Sepharose Fast Flow 
HighLoad 16/60 Superdex 75  
HighLoad 16/60 Superdex 200 
HighTrap DEAE Fast Flow 
MonoQ® HR 5/5 
PD-10 desalting columns 
Streptactin MacroPrep 
Superdex 75 10/300 GL 
Superdex 200 10/300 GL 
Superose 6 10/300 GL 
All columns and resins were from GE Healthcare, except Streptactin MacroPrep, which 
was purchased from IBA (Göttingen, G) 
 
 
2.1.5  Miscellaneous 
BioBond plus nylon membrane   Sigma, Lyon, F 
epT.I.P.S. Pipette tips (0.1-10µl)   Eppendorf, Hamburg, D 
epT.I.P.S.Pipette tips (10-200µl)   Eppendorf, Hamburg, D 
epT.I.P.S.Pipette tips (100-1000µl)   Eppendorf, Hamburg, D 
ep Dualfilter T.I.P.S. Pipette tips (0.1-10µl)  Eppendorf, Hamburg, D 
ep Dualfilter T.I.P.S. Pipette filtre tips (20-300µl) Eppendorf, Hamburg, D 
ep Dualfilter T.I.P.S. Pipette filtre tips (100-1000µl) Eppendorf, Hamburg, D 
PCR tubes      Eppendorf, Hamburg, D 
Tubes (50 and 15ml)     BD Biosciences, San Jose CA, USA  
Tubes (1.5 and 2ml)     Eppendorf, Hamburg, D 
MATERIALS & METHODS 
 
28 
 
Tubes (1.5 and 2ml, without lid)   TreffLab 
Tubes (5ml)      BD Biosciences, San Jose CA, USA  
Petridishes      BD Biosciences, San Jose CA, USA  
Pipettes sterile plastic (5,10 and 25ml)  BD Biosciences, San Jose CA, USA  
Whatman paper     Whatman, GE Healthcare Europe,  
       Saclay, F 
 
 
2.1.6  ENZYMES 
AflII       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
BamHI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
Benzonase      Novagen, Darmstadt, D 
BsaI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
DNaseI (Deoxyribonuclease I)    Roche, Meylan, F 
DpnI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
Egg-white Lysozyme     Sigma 
HindIII       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
NcoI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
NdeI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
NsiI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
Pfu Polymerase     EMBL Heidelberg, D 
RNaseA (Ribonuclease A)    Roche, Meylan, F 
T7 Polymerase     EMBL Heidelberg, D 
TEV protease      EMBL Heidelberg, D 
Turbo Pfu      Stratagene 
XbaI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
XhoI       NEB, Ozyme, Saint-Quentin-en- 
       Yvelines, F 
 
 
2.1.7  BUFFERS, SOLUTIONS AND MEDIA 
LB Medium (Luria-Bertani Medium)    20 capsules 
(from QBiogene, Illkirch, F)     Ad 1L H2Od 
        autoclaved 
10x Electro-blotting Buffer for Nylon membranes  0.1M Tris-acetate, pH 7.8 
        50mM Na-Acetate 
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50x TAE buffer (Tris-Acetate-EDTA)    2M Tris base 
        57.1% (v/v) Acetic acid 
        0.05M EDTA pH8.0 
 
10x TBE buffer (Tris-borate-EDTA)    0.89M Tris base 
        0.89M Boric acid 
        0.02M EDTA pH 8.0 
 
TE buffer pH 7.4(Tris-EDTA)     10mM Tris HCL, pH 7.4 
        1mM EDTA, pH 8.0 
 
2x denaturing RNA loading buffer    8M Urea 
        1mM EDTA pH 8.0 
        0.02% Bromophenolblue 
        0.02% Xylene cyanol blue 
 
4x SDS protein sample buffer    200mM Tris HCl pH 6.8 
        20% (v/v) 2-Mercaptoethanol 
        8% (w/v) SDS 
        0.1% (w/v) bromophenol  
        blue 
        40% (v/v) glycerol 
 
10x SDS running buffer (tris-glycine)    0.25M Tris base 
       2.5M Glycine 
        1% (w/v) SDS 
 
4x native protein loading buffer    0.25M Tris HCL, pH 6.8 
        40% (v/v) Glycerol 
        0.1% bromophenolblue 
 
10x native running buffer     30g Tris base 
        144g Glycine 
        ad H2O 1L 
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4x denaturing protein sample buffer for Tris-Tricine gels 0.2M Tris HCL, pH 6.8 
        60% (w/v) Glycerol 
        16% (w/v) SDS 
        0.2M DTT 
        0.02% (w/v)Coomassie  
        brilliant blue G-250 
 
10x upper cathode running buffer for Tris-Tricine gels 1M Tris HCl pH 8.25 
        1% (w/v) SDS 
        1M Tricine 
 
10x lower anode running buffer for Tris-Tricine gels 2M Tris HCl, pH 8.9 
 
6x DNA loading buffer     10mM Tris HCl, pH 7.6 
        0.03% (w/v)  
        bromophenolblue 
        60% (v/v) Glycerol 
        60mM EDTA, pH 8.0 
 
 
Coomassie brilliant blue stain    45% (v/v) Ethanol 
        (v/v) Acetic Acid 
        0.25% (w/v) Coomassie  
        brilliant blue G-250 powder  
        ad H2O 
        Filter through Whatman  
        paper 
 
Methylene Blue stain      2% (w/v) Methylene Blue 
 
 
2.1.8  BUFFERS FOR PROTEIN PURIFICATION 
AFFINITY CHROMATOGRAPHY 
Proteins with His-Tag 
20mM Hepes pH 7.8, 100mM NaCl, 20mM Imidazole (lysis buffer, Buffer1) 
20mM Hepes pH 7.8, 100mM NaCl, 50mM Imidazole (washing buffer)  
20mM Hepes pH 7.8, 1M NaCl, 1M KCl (removal of nucleic acids) 
20mM Hepes pH 7.8, 100mM NaCl, 500mM Imidazole (elution buffer) 
 
Proteins with Strep-TagII 
20mM Hepes pH 7.8, 100mM NaCl (lysis/washing buffer) 
20mM Hepes pH 7.8, 1M NaCl, 1M KCl (removal of nucleic acids) 
20mM Hepes pH 7.8, 100mM NaCl, 10mM ATP, 10mM KCl (removal of chaperones) 
20mM Hepes pH 7.8, 100mM NaCl, D-Desthiobiotin (elution buffer) 
 
Proteins with MBP-Tag 
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20mM Hepes pH 7.8, 100mM NaCl (lysis/washing buffer) 
20mM Hepes pH 7.8, 1M NaCl, 1M KCl (removal of nucleic acids) 
20mM Hepes pH 7.8, 100mM NaCl, 10mM Maltose (elution buffer) 
 
Proteins with GST-Tag 
20mM Hepes pH 7.8, 100mM NaCl (lysis/washing buffer) 
20mM Hepes pH 7.8, 1M NaCl, 1M KCl (removal of nucleic acids) 
20mM Hepes pH 7.8, 100mM NaCl, 10mM Glutathion adjusted to pH7.8 with NaOH 
 
ANION EXCHANGE 
 
20mM Hepes pH 7.8, 100mM NaCl 
20mM Hepes pH 7.8, 1M NaCl (Elution buffer) 
 
GELFILTRATION 
 
20mM Hepes pH 7.8, 100mM NaCl   Buffer 1 
20mM Hepes pH 7.8, 20mM NaCl     Buffer 2 
 
BUFFERS FOR RNA PURIFICATION 
3M Na-Acetate, pH 5.3 
0.1M Na- Acetate, pH 5.3 
Both buffers were filtered through a 0.2µM filter. 
 
2.1.9  BACTERIA STRAINS 
XL10 gold       Stratagene, La Jolla, CA, USA 
Genotype : TetrD(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]. 
DH5α subcloning efficiency     Invitrogen, Cergy pontoise, F 
Genotype : F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk -, mk +) phoA 
supE44 thi-1 gyrA96 relA1 λ- 
BL21(DE3)       Novagen, Darmstadt, D 
Genotype: F– ompT hsdSB(rB– mB –) gal dcm (DE3) 
 
2.1.10 SOFTWARE 
PyMol    (DeLano)  
    http://www.pymol.org/ 
mFold 3.2 and 2.3  (Walter et al., 1994; Zuker, 2003)    
   http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi and  
    http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1-2.3.cgi 
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BLAST    (Gertz) 
blastn    http://blast.ncbi.nlm.nih.gov 
blastp 
 
Consensus secondary  (Deléage et al., 1997) 
structure prediction  http://npsa-pbil.ibcp.fr 
 
 
2.1.11 PLATFORMS 
Mass spectrometry   Institut Biologie Structurale (IBS, Grenoble) 
Electron microscopy   Unit of Virus Host Cell Interactions (UVHCI,   
     Grenoble)  
High Throughput Crystallization European Molecular Biology Laboratory (EMBL,  
     Grenoble) 
Proteomics core facility  European Molecular Biology Laboratory (EMBL  
     Heidelberg) 
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2.1.12  OLIGONUCLEOTIDES 
N FL expression constructs  
BamHI_Tev_N CGCGGATCCTGAGAATCTTTATTTTCAGGGCATGCCACCCAAGAGACGCCTGGTTGATGAC 
BamHI-N-Afl-re  CCG CTT AAG CTA GTT TAG ACC AGT CAC C 
P deletion expression constructs for crystallization 
NcoICT30pepP CATGCCATGGGGACCTCTGCACCCATGTTG 
CT30pepPBamHI CGCGGATCCTTATGGTATGATGTCCCACTCATCCGC 
pCDFp14fo ATGGTGCAGCTATCGAATGATGAGC 
pCDFp14re ATGTATATCTCCTTCTTATACTTAACTAATATACTAAGATGGGGA 
X FL expression constructs for crystallization 
NotIXre ATAAGAATGCGGCCGCTCATTCGATAGCTGCTCCCTTCCG 
NcoIXfo CATGCCATGGACATGAGTTCCGACCTCCGGC 
BamHIXPfo CGCGGATCCCGAGAATCTTTATTTTCAGGGC 
HindIIIXPre CCCAAGCTTTCATTCGATAGCTGCTCCCTTCCG 
N point mutation and deletion expression constructs 
BDV-Nk164D 
/R165Afo 
GCAGGAGCCGAGCAGATCAAGGACGCCTTTAAAACTATGATGGCAGCCTTAAACCGG 
BDV-Nk164D 
/165Rre 
CCGGTTTAAGGCTGCCATCATAGTTTTAAAGGCGTCCTTGATCTGCTCGGCTCCTGC 
BDV-NK242Afo GCGCAGATGACTACGTACACTACTATAGCGGAGTACCTCGCAGAATGTATGGATGC 
BDV-NK242Are GCATCCATACATTCTGCGAGGTACTCCGCTATAGTAGTGTACGTAGTCATCTGCGC 
BDV-NR297Dfo ACGCTATCAAGCTTGCGCCAGACAGCTTTCCCAATCTGGCTTCTGC 
BDV-NR297Dre GCAGAAGCCAGATTGGGAAAGCTGTCTGGCGCAAGCTTGATAGCGT 
BDV-N_delNfo GACCCGCATCCGGGTATAGGG 
NshortRe GCC CTG AAA ATA AAG ATT CTC AGG ATC CTG GC 
BDV-N_delCfo TAGCTTAAGTCGAACAGAAAGTAATCGTATTGTACAC 
BDV-N_delCre [Phos]CGAGATATCTCGCGGCGCCTATAC 
BDVNQ161Sfo AGCATCAAGAAAAGGTTTAAAACTATGATGGCAGCCTT 
BDVNQ161Sre [Phos]CTCGGCTCCTGCTTTAATCT 
BDVNR287Dfo GATCACCCCGACGCTATCAAGCTTGC 
BDVNR287Dre [Phos]AATAGCCCCCAGGAACGGAAACAG 
P FL and deletion expression constructs 
pASKreCdelp CATGCCATGGTTATATGATGTCCCACTCATCCGCTG 
pASKNcoIrep CATGCCATGGTTATGGTATGATGTCCCACTCATCCG 
pASKBamHITevp CGCGGATCCCGAGAATCTTTATTTTCAGGGCATGATCTCAGACCCAGACCAGC 
pASKPCdel5new CATGCCATGGTTACTCATCCGCTGTCGGAGCACTT 
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BDV 5‘-RNA constructs 
SfiIT7rev TTTGGCCAAGTCGGCCTCTAA 
XbaBam40fo TCTAGAGGATCCGTGTAGTGCTTGGGCTTGGT 
XbaBam35fo TCTAGAGGATCCGTGCTTGGGCTTGGTTGTTGC 
XbaBam30fo TCTAGAGGATCCTGGGCTTGGTTGTTGCTTTGT 
XbaBam25fo TCTAGAGGATCCTTGGTTGTTGCTTTGTTGTAGCGC 
pGem9zfXbarev [Phos]TCTAGAGCAAAGCTTACTAGTGATGCATATTCTATAGTG 
 
2.1.13 PLASMIDS 
 
Figure 17: pETM-30 E. coli Expression Vector 
Plasmid provided by EMBL Heidelberg Protein Expression and Purification core Facility. 
The multiple cloning site is depicted in red. The plasmid provides a TEV-cleavable N-terminal His-GST (6x 
Histidine-Glutathion-S-Transferase)-Tag. Plasmid-containing bacteria are selected by acquired Kanamycin-
resistance. 
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Figure 18: pETM-40 E. coli Expression Vector 
Plasmid provided by EMBL Heidelberg Protein Expression and Purification core Facility. 
The multiple cloning site is depicted in red. The plasmid provides a TEV-cleavable N-terminal MBP 
(maltose-binding protein)-Tag. Plasmid-containing bacteria are selected by acquired Kanamycin-
resistance. 
 
 
 
 
Figure 19: pASK-IBA45 plus vector 
The multiple cloning site is depicted on the right. The plasmid provides an N-terminal StrepTagII and a C-
terminal His-Tag. The insert is under the control of a tet-promoter. Plasmid-containing bacteria are 
selected by aquired Ampicillin-resistance. 
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Figure 20: pGEM-9Zf(-) in-vitro transcription Vector  
Plasmid provided by Novagen. 
The multiple cloning site is depicted in a box together with the SP6 and T7 promoters. Plasmid-containing 
bacteria are selected by acquired Ampicillin-resistance. 
  
 
 
 
Figure 21: pCDF-Duet E. coli Expression Vector 
Plasmid provided by Novagen. 
It contains two multiple cloning sites (MCS1 and 2). And each insert is under the control of a T7-Promoter. 
The plasmid provides an N-terminal His-Tag in the first expression cassette and a C-terminal S-tag in the 
second. Plasmid-containing bacteria are selected by acquired Streptomycin-resistance. 
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2.2  METHODS 
 
2.2.1  CLONING OF EXPRESSION- AND IN-VITRO TRANSCRIPTION-CONSTRUCTS 
 
Cloning was carried out, according to standard cloning protocols, with the aid of the 
appropriate kits. The protocol for the generation of constructs with deletions and point-
mutations however is described more detailed in the next paragraph. 
DELETION AND SITE-DIRECTED MUTAGENESIS 
For deletion, oligonucleotide primers were designed in inverted tail-to-tail directions to 
amplify the cloning vector together with the target sequence. The deletion was 
generated by amplification with primers that have a gap between their 5' ends (Figure 
22, left). Point mutations were generated with a similar strategy, with primers with 
affiliating or overlapping 5’ends, one of which or both respectively, carried the desired 
mutation (Figure 22, right).  
 
 
Figure 22: Strategy for generating a deletion or point-mutation in a sequence cloned into a plasmid.  
Lines, blue boxes, small arrows and red x, indicate plasmid DNAs, target sequences, PCR primers and point 
mutations, respectively. PCR in inverted directions is done with primers that have a gap between their 5' 
ends or carry a mutation and affiliate/overlap, and the resulting DNA is self-ligated to transform E. coli. 
 
  
Plasmid Plasmid 
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One of two affiliating primers is phosphorylated at the 5’ end. After the PCR, amplified 
linear DNA was digested O/N with DpnI at 37°C to remove methylated template DNA, 
self-ligated and used to transform DH5α or XL10gold competent E. coli cells. The 
protocol was adapted and modified from (Imai et al., 1991). 
 
Components Volume 
  
Template DNA 50ng 
forward primer 
(10pM) 
1µl 
reverse primer 
(10pM) 
1µl 
Turbo-Pfu  DNA 
Polymerase 
0.5µl 
dNTPs (10mM) 1µl 
10x Pfu buffer 5µl 
H2O dd ad 50 µl 
Table 2: PCR composition 
 
Steps Temperature Duration Number of Cycles 
    
Initialization 95ºC 2min 1 
Denaturation 95ºC 1min 
18 Annealing 55-66ºC 1min 
Elongation 72ºC 1min/kb 
Final elongation 72ºC 10min 1 
 
Table 3: PCR cycles 
 
The annealing temperature was dependent on the Tm of the respective primers.  
 
2.2.2  EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS 
BDV-N (370 aa) and the BDV-N mutant N-CΔ24 were cloned into the pCDFDuet-1 vector 
(Novagen), containing an N-terminal His-Tag. N-CΔ24 comprises aa 43-370 of BDV N. 
Single and double aa substitution mutants N-K164D/R165D, N-K242A and N-R297D were 
cloned via site directed mutagenesis according to (Imai et al., 1991) with pCDFDuet-1 
containing full-length N as a template. K164D/R165D corresponds to Lys 164 and Arg 
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165 exchanged against an Asp each. K242A corresponds to Lys 242 changed to Ala, 
R297D contains an Asp instead of Arg at position 297. Gln 161 is substituted by Ser in 
Q161S. Proteins were expressed in E. coli BL21 (DE3)- Gold cells. Cells were harvested by 
centrifugation, resuspended in buffer 1 (20mM Hepes pH 7.8; 100mM NaCl) and lysed 
by sonication in presence of protease inhibitors (Complete EDTA-free protease 
inhibitors, Roche). The cleared supernatant was loaded onto a Ni2+- charged Chelating 
Sepharose (GE Healthcare) column. The column was washed in buffer 1 plus 1 M NaCl 
and 1 M KCl followed by extensive washes with buffer 1 plus 50mM Imidazole, pH 7.8. 
Proteins were eluted with Buffer 1 plus 500mM imidazole, pH 7.8. The His-tag was 
cleaved off overnight at 4ºC with TEV protease (1:100 w/w) in presence of 1mM DTT and 
1mM EDTA, pH 8.0. The tag was removed by a second Ni2+-Chelating Sepharose column 
after dialysis into buffer 1. Further purification was carried out via a MonoQ anion 
exchange column (GE Healthcare). Proteins were eluted by performing a salt gradient 
with buffer 1 plus 1M NaCl. 
A Superdex 200 size-exclusion column (GE Healthcare) was used as a final purification 
step in buffer 1. Protein concentration was determined by absorbance at 280 nm under 
denaturing conditions (6M guanidinium hydrochloride). BDV-N-P’ was co-expressed 
from pCDFDuet-1, but P’ remained untagged in order to co-elute with His-tagged N. 
Expression and purification was performed as described for BDV-N. BDV-P’ (146 aa, from 
aa 56-201) and C-terminal deletion P’ mutants P’-CΔ1 and P’-CΔ5 were cloned into 
pASK45-plus vector (IBA), containing an N-terminal StrepTagII. P’-CΔ1 comprises aa 56-
200 and P’-CΔ5 corresponds to aa 56-196. Proteins were expressed in E. coli BL21 (DE3)-
Gold cells. Production of cleared lysates was identical with that of BDV-N. Lysates were 
passed over a Streptactin sepharose column (IBA) and washed with Buffer 1, followed by 
buffer 1 plus 1 M NaCl and 1 M KCl and buffer 1 plus 10mM ATP, 10mM MgCl2. Elution 
was performed with buffer 1 plus 10mM Desthiobiotin. Further purification steps were 
performed as described for BDV-N. BDV-N, N-P’, P’ and P’ mutants were cloned by 
standard PCR methods, N mutants were cloned according to (Imai et al., 1991). All 
constructs were sequenced. 
BDV-X was expressed as an MBP-fusion protein in E. coli BL21(DE3) from pETM-40. Lysis 
was performed as for the other proteins and cleared lysates were purified via an 
Amylose resin (GE Healthcare). After washing with buffer 1 and buffer 1 plus 1M NaCl 
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and 1M KCl, the protein was eluted with buffer 1 plus 10mM Maltose. For the assembly 
of a BDV N-P-X triple complex E. coli pellets containing MBP-X and Strep-TagII-P’ were 
mixed and lysed together. The proteins were purified by using an Amylose resin, prior to 
mixing with purified and buffer1-dialysed His-N. This was done, since in a large scale 
purification, MBP-X did not bind to StrepTagII-P’ anymore, when P’ was already bound 
to His-N (unfortunately, this could not be confirmed with a small-scale pulldown assay). 
The proteins were incubated 10min, RT prior to purification by Ni2+-charged chelating 
Sepharose (GE Healthcare). The last affinity purification step was by Streptactin resin 
(IBA), where after washing with buffer 1, the proteins were eluted with buffer 1 plus 
1mM Desthiobiotin. Since further purification by anion exchange was never successful, 
the proteins were directly purified by gel filtration with a Superose 6 column (GE 
Healthcare) in buffer 1.  
 
2.2.3  IN-VITRO TRANSCRIPTION AND PURIFICATION OF BDV-RNA 
BDV-3’-Leader and 5’-Trailer RNA (BDV He/80/FR strain genome, GenBank AJ311522; 
nucleotides 1-125 and 8784-8909 respectively) were cloned into pGem-9zf (Novagen) 
and in-vitro transcribed after cleavage of the plasmid with NsiI (3’-RNA) and XbaI (5’-
RNA). The genome sequence entry in the NCBI nucleotide database for BDV He/80/FR 
corresponds to the trimmed genome as described (Pleschka et al., 2001) lacking 2 
nucleotides at the 5’ trailer for entire complementarity with the 3’ leader and ends with 
nucleotide 8909. Transcription reaction was carried out for 3-4 h at 37°C, modified from 
(Price et al., 1995). 
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IN-VITRO TRANSCRIPTION (LARGE SCALE) 
Components  
  
Linearized Template DNA 1-2mg 
Tris, pH8.0 100mM 
DTT 5mM 
NTPs 4mM each 
Triton X 0.01% (v/v) 
Spermidine 1mM 
MgCl2 25mM 
T7 Polymerase 7mg 
H2O dd ad 10ml 
 
Reaction was incubated for 3-4h at 37ºC 
Reaction stop was carried out by adding 2x RNA loading buffer. RNA was either 
immediately purified by denaturing urea-PAGE or size-exclusion chromatography or 
stored at -20ºC. 
 
RNA PURIFICATION (LARGE SCALE) 
20ml of RNA sample were loaded on 8-15% pre-heated denaturing Urea gels and was 
allowed to separate at a rating of 20 Watts for 6h. After visualization by UV shadowing, 
the corresponding band was excised and transferred into a 50ml plastic tube (Falcon). A 
sterile spatula was used to crush the gel to a smooth mass and 0.3M Na-Acetate pH5.3 
was added up to 50ml. RNA was allowed to elute by gentle agitation at 4°C, O/N.  
Eluate was passed through a 0.22µm filter unit (Millipore) and the gel was carefully 
scratched out with a sterile spatula for another elution-round with 50ml fresh Na-
acetate buffer (4°C, O/N). The filtration step was repeated.  
The obtained eluate was passed on a 1ml HiTrap-DEAE column (GE Healthcare), pre-
equilibrated with 0.3M Na-acetate pH 5.3. Column was washed with 10 CV of the 
mentioned buffer and RNA was eluted with 3M Na-acetate pH5.3. Isopropanol 
precipitation was carried out by adding 1 vol. of chilled Isopropanol and sample 
incubation at -80°C for 30min.  
After spinning the samples for 10min at 14000rpm, supernatant was decanted and 
pellets were washed with 70% ethanol. The resulting pellet was allowed to dry for 1h at 
RT. RNA pellets were dissolved in 2.5ml (final volume) nuclease-free H2O. A PD10 
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column (GE Healthcare) was used to desalt the RNA according to the protocol provided 
by GE Healthcare.  
RNA was finally concentrated to desired concentration by lyophilisation. 
 
2.2.4  POLYCRYLAMIDE GELELECTROPHORESIS (PAGE) 
Analysis of proteins and RNA was done by PAGE: 
Denaturing SDS-PAGE was performed according to (Schägger &  von Jagow, 1987; 
Ploegh, 1995) at 140V for Tris-Tricine PAGE and according to (Laemmli, 1970; Sambrook 
et al., 1989) for Tris-Glycine PAGE at 180V. Native PAGE for acidic proteins was 
performed at 100-120V with a modified recipe from Tris-Glycine PAGE, without SDS and 
a stacking gel. Denaturing Urea-PAGE for RNA analysis was performed according to 
(Price et al., 1995). 
 
2.2.5 SIZE-EXCLUSION CHROMATOGRAPHY MULTI-ANGLE LASERLIGHT SCATTERING  
(SEC-MALLS) 
SEC-MALLS is a relatively new and reliable technique for determining molar mass and 
molar mass distributions of macromolecules. Molecules are separated according to size 
by a size exclusion column and the light scattering signal from the eluting molecules is 
collected simultaneously at numerous angles (Wyatt, 1993; Jumel et al., 1996). The 
corresponding concentration trace is obtained downstream by a refractive index 
detector (Figure 23). For each point on the HPLC chromatogram, the amount of light 
scattered is directly proportional to the product of protein concentration and molar 
mass, according to Zimm’s formula for a diluted polymer solution (Wyatt, 1998; Gerard 
et al., 2007). The simplified formula for calculation of the molar mass is: 
 
𝑀𝑀 =  𝑅𝑅𝜃𝜃
𝐶𝐶𝐶𝐶∗
  
 
Whereas M is the molar mass (g/mol), Rθ is the measured excess Raleigh’s ratio, K* an 
equation-defined optical constant and C is the protein concentration.  
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Size exclusion chromatography was performed with a Shodex Protein KW-804 HPLC 
column (300 mm x 8.0 mm). Briefly, the column was equilibrated in buffer 1 and 
proteins were separated at 25 °C with a flow rate of 0.8 ml/min. On-line detection was 
performed by multi-angle laser light scattering (MALLS) using a DAWN-EOS detector 
(Wyatt Technology Corp., Santa Barbara, CA) equipped with a laser emitting at 690 nm 
and by refractive index measurement using a RI2000 detector (Schambeck SFD). Light 
scattering intensities were measured at different angles relative to the incident beam, 
and analysis of the data was performed with the ASTRA software (Wyatt Technology 
Corp., Santa Barbara, CA). 
 
 
Figure 23: Experimental setup for SEC-MALLS 
The sample is injected over a size-exclusion column and passes after separation and elution the indicated 
detectors. 
 
Weight-averaged (Mw) molecular weights were obtained from the molecular weight 
distribution across the elution peak. For both P’ and N-P’ complexes the molecular mass 
was constant across the elution peak. The polydispersity factor (MW/MN) equaled 1.00 
± 0.02 for P’ and 1.00 ±0.026 for N-P’ indicating monodisperse species in both cases. For 
regular size exclusion chromatography (SEC), stokes radii were determined by calibrating 
the column with globular proteins of known stokes radii. 
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2.2.6  CHEMICAL CROSS-LINKING 
N-P’ and StrepTagII-P’ (both in buffer 1) -samples of 20 µg were cross-linked with 0, 
0.1,0.2, 0.5, 1, 2 and 5mM Sulpho-ethyleneglycol bis(-succinimidylsuccinate) (Sulpho-
EGS, Pierce) or Glutaraldehyde (Sigma). The reactions were incubated for 20 minutes at 
room temperature and quenched by adding 4x SDS-PAGE sample buffer. Cross-linked 
material was analysed by discontinuous gradient Tris-Tricine-PAGE of 8 on 15% and 
bands were visualized by Coomassie Brilliant Blue. 
 
2.2.7  SURFACE PLASMON RESONANCE (SPR) MEASUREMENTS 
SPR allows the user to study the interaction between immobilized ligands and analytes 
in solution, in real time and without labeling of the analyte. Observed binding rates and 
binding levels can be interpreted in different ways to provide information on the 
specificity, kinetics and affinity of the interaction, or on the concentration of the analyte. 
It detects changes in the refractive index in the immediate vicinity of the surface layer of 
a sensor chip. SPR is observed as a sharp shadow in the reflected light from the surface 
at an angle that is dependent on the mass of material at the surface. The SPR angle 
shifts (from I to II in the lower left-hand diagram) when biomolecules bind to the surface 
and change the mass of the surface layer (Figure 24). This change in resonant angle can 
be monitored non-invasively in real time as a plot of resonance signal (proportional to 
mass change) versus time. 
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Figure 24: Setup for Surface Plasmon Resonance Biosensor 
The image was taken from (Cooper, 2002) 
 
To study the direct interaction between BDV-N and BDV-P’ the (SPR) technique on a 
Biacore 2000 instrument and reagents from Biacore AB (Germany) were used. 
Immobilization of the ligand (BDV-N) was performed via amino coupling on a CM5 
sensor chip. BDV-N (treated with 10mM acetate buffer, pH 4.5) was injected over a flow 
cell (activated with EDC/NHS) and immobilized to 8,800 response units (RU). The flow 
cell was then deactivated with ethanol amine (EA). Another flow cell, activated with 
EDC/NHS and deactivated with EA was used as a reference cell. 
Immobilization and interaction analysis were performed at 25°C, using HBS as running 
buffer. Aliquots of 60 μl of analyte (BDV-P’) (0.8-16 μM) were injected at a flow rate of 
20μl/min over sensor chip surfaces. The signal in the reference cell was subtracted 
online during all measurements. Alternative, aliquots of 25μl BDV-P’ (6.4 μM) incubated 
with a DEWDIIP-peptide (0-280μM) were injected over sensor 
chip. Furthermore 6.4 μM of each BDV-P mutant were injected over sensor chip. 
Evaluation of binding specificity and kinetics of interaction were performed using the 
BIAevaluation 3.2RC1 software (Biacore). 
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2.2.8  LYSINE METHYLATION 
Treatment of proteins with ABC (dimethylamine-borane complex), leads to the reductive 
methylation of lysines, thereby reducing surface entropy, which can have a favourable 
effect on crystallisation and may thus lead to improved diffraction (Rayment et al., 
1993). Since this modification is performed on purified mature proteins, there is no 
misfolding induced and only those residues on the exposed protein surface are modified 
while others remain protected within the core. 
Lysine-methylation of proteins was adopted and slightly modified from the protocol of 
(Walter et al., 2006). The methylation reaction was performed overnight in 50mM 
HEPES (pH 7.5), 250mM NaCl at protein concentrations of 0.1mg/ml or 5mg/ml. 20µl of 
freshly prepared 1M dimethylamine- borane complex (ABC; Fluka) and 40µl 1M 
formaldehyde (made from 37% stock; Fluka) were added per ml protein solution, and 
the reactions were gently mixed and incubated at 4°C for 2h. The procedure was 
repeated once, followed by a final addition of 10µl ABC and overnight incubation at 4°C. 
To remove precipitated protein, the sample was spinned for 5min at 14000rpm and 
filtered carefully and consecutively through filters with 0.4 and 0.2µm pore size. The 
reaction was quenched and reaction components were removed by buffer exchange 
into 20mM Tris, pH 7.5, 200mM NaCl via a PD10 column (GE Healthcare). The sample 
was again buffer-exchanged into Buffer 1 and concentrated prior to crystallization 
experiments. 
 
2.2.9  CRYSTALLIZATION OF BDV MACROMOLECULAR COMPLEXES 
All protein-protein-, protein-RNA-complexes and RNA were purified to homogeneity and 
sent, at different concentrations (Table 5) to the High-throughput crystallization facility 
(EMBL Grenoble, https://htxlab.embl.fr). Except BDV 5’-RNA (sent in 2mM MgCl2) all 
proteins were sent in buffer 1. N-5’-RNA complexes were purified as described in (see 
2.2.3) 
After screening for initial hits, N-P’ crystals were grown in hanging drops. Crystals grew 
(amongst similar conditions) at room temperature using reservoir buffer containing 
0.1M Hepes, pH 7.0; 2M Ammoniumphosphate by pipetting 1-2µl of protein solution 
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into 1-2µl of reservoir solution. Several attempts were made to improve the crystal 
morphology from plates to singular 3-dimensional crystals, including the addition of 1-
20% Glycerol, raising and lowering the concentration of the precipitant, pH screen, 
buffer exchange and adding the Hampton additive screen. A better crystal was obtained 
by addition of 30mM CaCl2. All N-P constructs led to crystals of identical morphologies 
which grew in similar conditions. They contained either high molarities (0.8-2M) of 
Ammoniumphosphate or –sulphate and a pH between 7 and 8.5. Further screening 
around the initial conditions was performed, but crystal improvement was not 
successful. 
 
Construct Concentration 
BDV N-P’ 10, 6 and 3mg/ml 
BDV N-P67-201 6 and 3mg/ml 
BDV N-P169-201 7 and 3.5mg/ml 
N+ P195-201 (DEWDIIP) 7mg/ml + peptide 1:1, 1:2 and 1:3 molar 
excess respectively 
P’ 15, 10 and 5mg/ml 
N-P’-X 6 and 3mg/ml 
N +BDV 5’-RNA (25nt) 18, 5 and 4mg/ml 
BDV 5’-RNA (25nt)  2, 1 and 0.5mg/ml 
Table 5: Concentration of constructs sent to the crystallization platform 
 
BDV N and putative BDV N-P169-201 (Figure 13) crystals grew at room temperature in 
0.1M Bicine pH9 or MES pH 6/6.5 and 5-20% PEG 6000. No further screening was 
necessary in this case. 
N crystals were soaked with the P derived C-terminal peptide P195-201 (DEWDIIP), 
applying the following strategies: 
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1. 0.5µl of peptide (in 20mM Hepes, pH 7.8) was directly added to a 2µl drop, 
containing crystals, thus that the molar N to peptide ratio was 1:3. 
2. The peptide was taken up in the respective condition and Hepes pH7.8 and NaCl 
were added thus that conditions corresponded to those, the nucleoprotein 
crystals grew in. 1µl of the mixture was added directly to the crystal-containing 
drops, at the ratio corresponding to 1. 
3. The peptide was treated as in 2. 2µl of the mixture were pipetted onto a cover 
slip and nucleoprotein crystals were fished out of their initial drop and 
transferred to the new drop which was containing the peptide. 
All other crystallization attempts from table produced no initial hits. 
N-P’ crystals were cryo-protected in reservoir solution containing 20-30% glycerol, 
whereas the best diffracting crystal was frozen with 25% glycerol. N (-P169-201) and N 
crystals soaked with P195-201 were frozen with reservoir solution, containing 20% glycerol. 
Crystals were harvested in nylon loops and plunged into liquid nitrogen (for storage until 
data collection) or directly frozen in the beam line cryo-stream. Complete data sets were 
collected at ESRF beam lines ID23-2 and ID14-2. 
 
2.2.10 N-RNA and N-P’-RNA interaction  
SEC purified N and N-P’ were incubated overnight at 4°C with a 2M excess of BDV-3’-
Leader-, 5’-Trailer- and total E. coli RNA in buffer 3 (20mM Hepes, 20 mM NaCl, pH 7,8) 
and in absence and presence of Urea (1, 2, 3 and 4 M). The effect of Urea on N and N-P’ 
alone was tested by incubation with 4 M Urea. Samples were analyzed by 6.5% native 
PAGE and stained with Coomassie Brilliant Blue after verifying RNA presence by 
Methylene Blue staining. Furthermore, N, N-P’ and P’ were incubated overnight at 4°C 
with a 2M excess of BDV-5’-Trailer RNA (125 nucleotides) to verify that P’ does not 
interact with RNA. Samples were analyzed by discontinuous gradient 6.5 on 16% native 
PAGE and stained with Coomassie Brilliant Blue after verifying RNA presence by 
Methylene Blue stain. The same experiments were performed with N carrying specific 
point mutations. 
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2.2.11 ELECTRON MICROSCOPY.  
BDV-N was purified by SEC and analyzed by electron microscopy (Electron microscopy 
platform, Grenoble) using negative staining with sodium silicotungstate (pH 7.0). The 
grids were observed using a JEOL 2010 FEG electron microscope working at 100kV with a 
nominal magnification of 40.000 (Schoehn et al., 2001). Gel filtration purified N was 
incubated with BDV-5’-Trailer- RNA (125 nucleotides) in buffer 3 and purified by glycerol 
gradient centrifugation. The gradient was continuous from 45% glycerol at the bottom 
to 25% at the top. Glycerol was buffered with buffer 3. Samples were spun for 16h at 4°C 
and 40000 rpm in an ultracentrifuge (Beckman). Samples present in the bottom fractions 
were collected and analyzed by electron microscopy. 
  
2.2.12 RNASE PROTECTION ASSAY  
N-RNA and N-P’-RNA were purified as described above for electron microscopy analyses. 
Complexes were incubated for 15 min at 37° with 0.05, 0.1, 0.2 and 0.5μg/ml RNase A 
(Roche). Controls were performed with buffer 3 instead of RNase A. 
After incubation samples were treated with RNAGuard RNase inhibitor (GE Healthcare) 
and stored on ice prior to further treatment. One half was boiled with 8M Urea before 
subjection to a 16% denaturing polyacrylamide-urea gel. The gel was stained with 
ethidiumbromide. The other half was mixed with a 4x native PAGE sample buffer and 
samples were separated by 6.5% native PAGE. The bands were visualized with 
Coomassie Brilliant Blue staining. 
 
2.2.13 RNASE PROTECTION ASSAY WITH DIG-LABELED RNA.  
DIG-labeled BDV-5’-RNA (125 nucleotides) was incubated with N and N-P’ or buffer 3 as 
a control. N-RNA and N-P’-RNA were incubated for 15min at 37°C with 0.05, 0.1 and 
0.2μg/ml RNase A. After incubation samples were treated with RNAGuard RNase 
inhibitor (GE Healthcare) and subjected to 18% denaturing Urea PAGE. Samples were 
electro-blotted to a nylon membrane (Sigma) according to (Günzl et al., 2002). Band 
detection was performed with alkaline phosphatase-conjugated anti-DIG-Fab-fragments 
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(DIG northern starter kit, Roche), following the manufacturers protocol for direct 
detection. 
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3  RESULTS 
3.1  EXPRESSION AND PURIFICATION OF BORNA DISEASE VIRUS PROTEINS  
Previous studies (like in silico secondary structure and disorder predictions, Figure 13) 
indicated that the full-length BDV phosphoprotein was not suitable for crystallization. 
Furthermore, its high susceptibility to degradation and tendency to precipitate at higher 
concentrations, lead to the decision to express and purify the N-terminal truncated 
isoform of P termed P’ (aminoacids 56-201). Thus, P’ has been used for most of the 
experiments, since it exhibits better solubility at higher concentrations and higher 
stability upon storage. 
 
 
Figure 13: Secondary structure consensus prediction for BDV P.  
The Sequence of P’ is depicted in red, the boxes indicate the other P constructs used for crystallization: 
P67-201 (blue), P169-201 (green), P195-201 (yellow). The prediction is displayed below the sequence as follows: 
Alpha helix(Hh), Extended strand (Ee), Random coil (Cc), Ambiguous states (?). Prediction was performed 
on the NPS@ platform (http://npsa-pbil.ibcp.fr). 
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Figure 14: Purification of BDV P’  
Denaturing SDS-PAGE analysis of affinity purification of BDV P’, containing a non-cleavable N-terminal 
StrepTagII, with a) showing the flowthrough and the different washing steps and b) the elutions with 
Desthiobiotin from a Streptactin sepharose column. c) Anion exchange chromatography elution profile of 
BDV P’. The blue line shows the UV absorption (left ordinate axis in mAU) at 280, the dashed red line at 
260nm. The concentration of the high salt (HS) buffer (right ordinate axis, in %) is depicted by a yellow 
line. The peak fractions are indicated by bold black bars on the X-axis, together with the elution volume. d) 
Analysis of anion exchange peak fractions from c) by 16% denaturing SDS-PAGE. P’ bands are indicated by 
an arrow. Fractions 14-18 were pooled and subjected to gelfiltration. e) Gelfiltration elution profile and f) 
analysis of the indicated fractions by 16% denaturing PAGE. All bands were visualized by Coomassie 
brilliant blue. The molecular weights in (kDa) of marker proteins (M) are indicated on all gels. 
 
As all other BDV proteins, P’ was expressed as a recombinant protein with a cleavable or 
non-cleavable (as in Figure 14) StrepTagII in E. coli, allowing affinity purification via a 
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Streptactin matrix (IBA, Göttingen), (Figure 14 a). The protein was finally purified to 
homogeneity by anion exchange and size exclusion chromatography (Figure 14 c-f).  
 
 
 
Figure 14: Purification of BDV N-P’ 
a) Denaturing PAGE analysis of N-P’ expression in E. coli before (b.I.) and after induction (a.I) and 
purification of the protein complex by a Ni2+-charged chelating Sepharose column with the different 
washing steps, including a high-salt (HS) wash. The proteins are indicated by arrows. b) His-tag removal 
from N by TEV protease cleavage. Lane 1 shows uncleaved N, lanes 2 and 3 show N after cleavage, before 
and after purification via a second Ni2+-charged chelating Sepharose column, respectively. c) Anion 
exchange chromatography elution profile of N-P’. The blue line shows the UV absorption (left ordinate axis 
in mAU) at 280, the dashed red line at 260nm. The concentration of the high salt (HS) buffer (right 
ordinate axis, in %) is depicted by a yellow line. The peak fractions are indicated by bold black bars on the 
X-axis, together with the elution volume. d) Analysis of anion exchange peak fractions from c) by 16% 
denaturing SDS-PAGE. N and P’ bands are indicated by arrows. Fractions 32-35 were pooled and subjected 
to gelfiltration. e) Size-exclusion chromatography elution profile and f) analysis of the indicated (bold bars 
on X-axis) fractions by 16% denaturing PAGE and g) 7% native PAGE. All bands were visualized by 
Coomassie brilliant blue. The molecular weights in (kDa) of marker proteins (M) are indicated on all gels. 
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The protein eluted at 11.31ml from a Superdex 200 (GE Healthcare) gelfiltration column 
(Figure 14e). Similarly BDV N and P’ were co-expressed in E. coli (Figure 15), whereas the 
untagged P’ was co-purified with a His-tagged nucleoprotein by a Ni2+-charged affinity 
resin (Figure 15). 
After cleavage of the His-tag by TEV-protease, the N-P’ complex was purified to 
homogeneity by anion exchange and gelfiltration (elution peak at 10.77ml) (Figure 15c-
g). Both purified recombinant P’ and N-P’ complexes eluted from a size exclusion 
chromatography column as single peaks (Figure 14e and 15e).  
 
3.2  PROPERTIES OF P’ AND N-P’ OLIGOMERS  
The molecular weight determined by multi-angle laser light scattering (MALLs) revealed 
a molecular weight of 75.57± 0.35 kDa for P’ corresponding to a tetramer (the 
theoretical MW of a tetramer is 75.397 kDa) (Figure 15a) and of 235.3± 9 kDa for the N-
P’ complex consistent with a P’ tetramer interacting with the N tetramer (calculated MW 
of the heterooctamer is 233.99 kDa) (Figure 15b). 
These results were further confirmed by chemical cross-linking of N-P’ complexes or P’ 
alone (see 2.2.6). Therefore, 0.5 mg of N-P’ and P’ were incubated with different 
concentrations of Glutaraldehyde and ethylene glycol bis[succinimidylsuccinate] (EGS). 
The cross-linked proteins were analyzed by SDS-PAGE as shown in Figure 16. Since BDV-
P’ carried an N-terminal Strep-Tag and a TEV-protease cleavage site, the P’ control 
migrates at ~23kDa instead of 16kDa. Cross-linking revealed intermediate states of P’ 
(migrating at ~ 50 and ~70 kDa) and the fully cross linked P’ migrating at ~90 kDa (Figure 
16a). BDV N-P’ cross-linking is shown in figure 16b. Multiple bands are visible between 
~50 and 200 kDa at lower cross-linker concentrations. The highest bands migrate at 
~250 kDa, which is roughly consistent with a hetero-octameric N-P’-complex. 
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Figure 15: Molecular weight of BDV-P’ and BDV-N-P’ determined by multiangle laser light scattering and 
refractometry combined with size-exclusion chromatography (MALLS).  
a) BDV-P’ and b) BDV-N-P’ SEC elution profiles revealing molecular weights of ~75 kDa for P’ and ~235 kDa 
for N-P’. The dashed line shows the elution profile 24 monitored by excess refractive index (left ordinate 
axis). The black line shows the molecular mass distribution (right ordinate axis) determined by MALLS and 
refractometry data. 
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Figure 16: Chemical crosslinking of BDV P’ and N-P’ 
a) Analysis of BDV P’, cross-linked with different concentrations of EGS and Glutaraldehyde, by Tris-Tricine 
discontinuous-gradient (10 over 16%) PAGE. b) The same as a) but with the BDV N-P’ complex. The used 
cross-linking reagents EGS and Glutaraldehyde and their concentrations are indicated at the bottom in 
milli Molar (mM), M indicates the lane with the marker proteins. Bands were visualized with Coomassie 
brilliant blue. 
 
3.3  AFFINITY OF THE N-P’ INTERACTION 
The affinity of the N-P’ interaction was determined by surface plasmon resonance (SPR) 
measurements (see 2.2.7).  
Binding of BDV-P’ to immobilized BDV-N was performed with different analyte (P’) 
concentrations. The experiments showed rapid protein-protein association and fast 
dissociation (Figure 17a). Binding association curves enabled the calculation of the KD by 
plotting SPR values for each injection as a function of the concentration of BDV-P’ (08-
16μM) added. A bimolecular binding model was determined based on the interaction 
data and used to compute the binding constant (KD) of ~ 1.66μM, fitting the 
experimental data with a closeness of fit χ2 of 1.6. Individual rate constants were 
determined for kon, ka to be 1.8x10
3 (1/ms) and for the koff, kd to be 3x10-3(1/s). Since 
deletion of the C-terminal four residues of P’ abrogates N interaction (Schwemmle et al., 
1998) a peptide composed of the C-terminal 7 amino acids (sequence: DEWDIIP, P195-201) 
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was used as analyte. Although no response signal was detected with this peptide alone 
(data not shown), it showed an effect in a competition assay. Incubation of the peptide 
with full-length BDV-P’ as analyte prior to injection over immobilized BDV-N decreased 
the SPR-signals proportional to the increase of peptide concentration (Figure 17b). This 
confirmed that the C-terminal seven P’ residues are important for N interaction, which 
was further corroborated by pull-down assays. Deletion mutants of P’ lacking either 1 (P-
CΔ1) or 5 C-terminal amino acids (P-CΔ5) (see Figure 17c) were used to pull down N 
upon co-expression. P’ was labeled with a Strep-TagII and N carried a His-Tag. Full-length 
P’ co-eluted with N (Figure 17c, lanes 1 and 4) as well as P-CΔ1 (Figure 17cc, lanes 2 and 
5) but not with P-CΔ5 using pull down via the Strep- or the His- Tags (Figure 17c, lanes 3 
and 6). 
Together these results suggest that a short C-terminal linear peptide region of P is 
required for a low affinity interaction with N. 
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Figure 17: Characterization of the N-P’ interaction.  
a) Specificity of BDV-P’ binding to BDV-N Plot of sensorgrams associated to injection of BDV-P (c=0-16μM) 
to immobilized BDV-N. The arrows indicate the association and dissociation phase respectively. The 
dissociation constant was evaluated according to a 1:1 binding model with drifting base line as 1.66μM. b) 
Decrease of interaction between BDV-P’ and BDV-N due to the blocking of binding sites on BDV-P’ by a C-
terminal peptide of the BDV phosphoprotein with a length of 7 amino acids (see Figure 13, yellow box). 
BDV-P’ (6.4μM) was injected over the sensor chip surface coupled with BDV-N after prior incubation at 4°C 
of 30 min with the peptide (c=0-280μM). c) Pull down assay of N with C-terminal P’ mutants. All pull 
downs were performed with Ni2+-agarose beads and streptactin resin simultaneously. Proteins were 
separated by 16% SDS-PAGE and visualized by Coomassie brilliant blue stain. The asterisk indicates the 
bands of the different P proteins StrepTagII-P’ (lanes 1 and 4), -P-CΔ1 (lanes 2 and 5) and –P-CΔ5 (lanes 3 
and 6). Lanes 1-3 indicate Ni2+-, lanes 4-6 indicate streptactin-purified protein. 
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3.4  CRYSTALLIZATION AND PRELIMINARY X-RAY ANALYSIS OF THE BDV 
NUCLEOPROTEIN-P’ COMPLEX 
After concentration of the purified complex (see Figure 15) to ~5mg/ml it was exposed 
to 576 crystallization conditions at 20°C in sitting nano-drops (High-Throughput 
crystallisation platform, EMBL Grenoble). Crystals were obtained after two weeks in 
numerous conditions (see 2.2.9). Reproduction of the initial hits using the same protein 
sample has been successful in larger drops of 2µl. Those crystals were not yet subjected 
to an X-ray beam, but washed with mother liquor prior to pooling and analysis by SDS-
PAGE. Neither Coomassie nor subsequent silver staining of the gel revealed 
interpretable bands. Since neither protein nor crystals were left, fresh N-P’ samples 
were purified. However, crystals could not be reproduced in these conditions. The 
failure may be explained by the age of the samples and resulting protein degradation. 
While the age of the new batches did not exceed 4 days; the age of the initial sample 
however, surpassed two weeks which probably lead to protein degradation that may 
have facilitated crystallization. Reproducible crystals were finally obtained in conditions 
containing high concentrations of Ammoniumphosphate or –sulphate (Figure 18). 
The crystals were made up of thin plates which were stuck within and overlaying each 
other (Figure 18a). Subjection to an X-ray beam gave rather poor diffraction (~ 6Å) and 
crystals had to be improved with an additive screen (Hampton).  
 
Figure 18: Crystals of N-P’ 
a) Crystals obtained with BDV N-P’ in 0.1M Hepes, pH 7.0; 2M Ammoniumphosphate. b) Crystal grown at 
the same conditions as in a) with 30mM CaCl2 as an additive. c) Same crystal as in b) in a nylon loop after 
exposure to an X-ray beam. 
 
A single triangular crystal (within vast numbers of microcrystals) grew after of 30mM 
CaCl2 were added to the initial condition. Observed through a light microscope with 
polarizing optics, the crystal showed high birefringency and sharp edges. 
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A complete data set was collected at ESRF beam line ID14-2 (Grenoble, France). The 
crystal diffracted to 4Å (Figure 19) and belongs to space group C2 with unit cell 
parameters of a= 276Å, b= 81Å and c= 81.5Å. Data were indexed and integrated with the 
MOSFLM (Leslie, 1992) and XDS (Kabsch, 1993) packages and scaled using SCALA 
(Collaborative Computational Project, 1994). Data-collection statistics are listed in Table 
6. Structure determination was attempted by molecular replacement using MOLREP 
(Collaborative Computational Project, 1994) and a search model corresponding to BDV N 
(Protein Data Bank code 1PP1) (Rudolph et al., 2003). Unfortunately, no extra density 
indicated the presence of P’ or a P’-derived peptide.  
 
DATA COLLECTIONa BDV N-P’ 
Resolution (Å) 4.04- 29.92 
Rmerge (%) 14 
Space group C2 
Unit Cell parameters a, b, c (Å) 276x81x81.5 
α β γ 90° 98° 90º 
Number. of Molecules/ Asymmetric Unitb 1 
Number of Reflections 13840 
Wilson B factor (Å2) 122.474 
Table 6: Crystal Data of BDV N-P’  
aData were collected from single crystals at the beamline ID14-2 at the European Synchrotron Radiation 
Facility (ESRF), Grenoble, France. 
bEstimated using Matthews coefficient probabilities (corresponding solvent content of 60.88 %). 
 
One explanation is that P’ degraded and remained undetected due to the rather poor 
resolution; or N crystallized alone because of the dissociation of N-P’ in the respective 
condition. Further crystal improvement by modulation of the initial hit conditions (see 
2.2.9) led to the formation of large, birefringent crystal plates with mostly irregular 
edges. All of them were tested on beamline ID 23 (ESRF Grenoble) but turned out to be 
of inorganic origin. The high abundance of salt crystals and the unsuccessful 
reproduction of protein crystals indicate that the latter is probably dependent on a 
highly sensitive equilibrium within the crystallisation drop. 
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Figure 19: X-ray diffraction pattern of BDV N-P’ 
The white circle marks 4Å.  
 
3.4.1  CHANGE OF STRATEGY: CRYSTALLIZATION OF BDV N-P67-201 AND 
  N-P169-201 
Compact globular proteins are rather suitable for crystallization than those exhibiting 
high degrees of flexibility. Thus, limited proteolysis is used as a tool to identify compact 
protein segments, since they are generally not accessible for proteolytic enzymes, such 
as e. g. trypsin. Purified N crystallizes easily and exhibits a compact structure, thus I 
assumed that P’ was responsible for the unsuccessful crystallization trials (see 3.3 and 
2.9), as it was predicted to contain large disordered regions (Figure 13). In consequence, 
P’ was subjected to limited proteolysis with trypsin (Figure 20) to identify a stable core, 
rather suitable for co-crystallisation with the nucleoprotein.  
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Figure 20: Limited Proteolysis of BDV P’ with Trypsin 
50 μg of purified P’ was incubated for 10 min at 37°C with protein:trypsin ratios of 1:500 1:100 
and 1:50 (lanes 2-4). A reaction without trypsin was carried out as a control (lane 1). Reactions 
were stopped by boiling the sample in SDS sample buffer, and the digested products were 
analyzed by 16% denaturing SDS-PAGE. Marker (M) bands are visible at the very right. Stain: 
Coomassie brilliant blue.  
 
A band migrating at ~14 kDa was identified and sent for N-terminal sequencing. The 
identified sequence started at Glu67 and a respective construct (P67-201) was generated 
for co-crystallisation trials with the BDV nucleoprotein. Figure 21 shows the last 
purification step of the N-P67-201 complex. Crystals appeared, but did not differ in 
morphology or growth-conditions from those shown in Figure 18a. This led to the 
assumption that further N-terminal truncation of P67-201 was necessary.  
The consensus disorder prediction (Figure 13) of BDV P showed a disordered stretch of 
~30 amino acids, comprising the interaction domain with N at the very C-terminus. 
Folding is sometimes induced on regions of intrinsic disorder upon association with an 
interaction partner (Wright &  Dyson, 1999; Uversky, 2002; Uversky, 2002). Assuming 
this was probably the case for the c-terminal region of BDV-P upon interaction with N, a 
new construct was generated. It comprised the C-terminal 33 amino acids of P and was 
expressed as a His-GST-fusion peptide (P169-201, Figure 13, green box). 
RESULTS 
 
63 
 
 
Figure 21: Purification of N-P67-201 
a) Size-exclusion chromatography profile of BDV N-P67-201 after affinity chromatography, TEV- cleavage and 
anion-exchange. UV absorption peak is depicted in red at 260nm and in blue at 280nm. Fractions, taken 
for analysis and crystallisation are marked by bold black bars on the X-axis. Every second fraction number 
is depicted b) Denaturing SDS-PAGE analysis of size exclusion chromatography fractions on 16% gel. M 
indicates the marker proteins. Bands were visualized with Coomassie brilliant blue.  
 
P169-201 was co-purified to homogeneity in complex with N (Figure 22) and sent to the 
High-Throughput crystallization facility (EMBL Grenoble) for crystallization. Again, 
crystals similar to those in figure 18a appeared under the same respective conditions 
after two days. Hence, upscaling and improvement was not directly performed, but the 
complex was further treated with the dimethylamine-borane complex (ABC, Fluka). 
Treatment with ABC leads to the methylation of lysines, exposed on the protein surface, 
which reduces protein flexibility and may thus facilitate crystallization (see 2.2.8) 
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Figure 22: Purification of N-P169-201 
a) Denaturing SDS-PAGE analysis of glutathion-S-transferase (GST) affinity-purification of His-N with His-
GST-P-NΔ168 from a glutathion-sepharose column. Flowthrough and washing steps are indicated. Proteins 
were eluted with 10mM reduced glutathion. b) Affinity tags were cleaved off with TEV-protease and 
proteins were subjected to a Ni2+-charged chelating sepharose column for separation from the affinity 
tags. Samples were analysed by 16% SDS-PAGE. Lane 1 shows an uncleaved protein complex, lane 2 the 
elution sample containing His-GST and lane 3 shows N in the flowthrough. Since P169-201 could not be 
deteced, the sample was subjected to c) 7% native PAGE together with purified and cleaved N as a control 
(lane 1) in order to verify complex assembly (lanes 2-4). Note that both N-control and complex were on 
the same gel. d) Size-Exclusion chromatography profile of N-P169-201 of the pooled samples from c) lanes 2-
4. The blue line depicts the UV absorption per ml at 280nm, the red line at 260nm. Stain: Coomassie 
brilliant blue. All proteins are indicated (arrows and bars). e) SDS-PAGE analysis of a pulldown experiment 
after mixing ABC-treated N with His-GST-P169-201. Sample was subjected to a glutathion-sepharose 
column. After washing (flowthrough and washing steps are indicated) proteins were eluted with 10mM 
reduced glutathion. Note that 3 bands migrate around 37 kDa, mostprobably due to partial degradation of 
BDV N.  
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Proteins were again subjected to the crystallization robot and simultaneously sent for 
mass spectrometry (MALDI-TOF) (PSB platform, IBS, Grenoble) to verify that the N-P169-
201 complex sustained ABC treatment. Crystals appeared 3 days after in 5-15% PEG 6000 
and 100mM of the buffers Bicine pH 9 or MES pH 6.5. The crystal morphology 
corresponded to those in figure 23a, generally obtained with the nucleoprotein alone. 
Larger crystals were produced, which diffracted to ~1.7 Å. However, the structure 
obtained by molecular replacement revealed only the nucleoprotein. The data were 
identical to those reported by Rudolph et al., (Rudolph et al., 2003). 
Regarding the crystal lattice, the N-tetramers were tightly packed within the crystal, 
which hardly left any space for another compound to bind. Additionally, the putative 
interaction domain with BDV-P (amino acids 51-100), (Berg et al., 1998)) is involved in 
crystal contacts with the C-terminal domain of a neighbouring molecule.  
The results from mass spectrometry (MALDI-TOF) of an N-P169-201 sample confirmed that 
P169-201 was not present in the sample anymore after treatment with ABC. The sample 
used for crystallisation had a mass of 41505 Da, which is approximately consistent with 
the theoretic mass of a nucleoprotein tetramer with 20 methylated lysines (the mass 
increases by 28 Da per methylated lysine; the total number of lysines in the 
nucleoprotein is 21). The mass was identical to the ABC –treated N-control, indicating 
that ABC treatment of N-P169-201 probably led to disruption of the complex and 
precipitation of P169-201.  
Thus, I tried to assemble the complex after independent purification and ABC treatment 
of one or the other protein. Both His-N and His-GST- P169-201 were purified independently 
and subjected to ABC treatment at two different concentrations (0.1mg/ml and 
5mg/ml). After filtration, the His-GST-P169-201 sample did not absorb UV light (at 280, 260 
and 230nm) anymore, indicating that it precipitated upon lysine methylation. ABC 
treated N however, partially degraded and did not co-elute with non-treated His-GST-
P169-201 from a glutathion-sepharose column (Figure 22e). This suggests either that 
lysines may be strongly involved in P-association or that the induced stability of N 
interfered with the interaction of the two proteins. Due to this outcome, a different 
strategy was applied. 
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3.4.2  CO-CRYSTALLIZATION OF THE BDV NUCLEOPROTEIN WITH THE 
PHOSPHOPROTEIN-DERIVED PEPTIDE P195-201 
A short peptide (Figure 13, yellow box) of 7 amino acids from the very C-terminus of P 
(195DEWDIIP201, P195-201) has been shown to be sufficient for interaction with the 
nucleoprotein (see 3.3, Figure 17b). Assuming that such a short peptide may not 
interfere with crystal formation, this peptide was added to purified N 12h prior to 
subjection to the crystallisation robot (see 2.2.9). No crystals appeared except those 
shown in figure 18a under the same respective conditions, which were of poor 
diffraction earlier. Thus, we decided to crystallise N alone with 10% PEG 6000 and 0.1M 
MES, pH 6 and soak the thus generated crystals with the peptide.  
 
3.4.3  SOAKING OF BDV NUCLEOPROTEIN CRYSTALS WITH P195-201 
Two crystal morphologies were obtained for N, exhibiting different stabilities in respect 
of dehydration of the drop: Figure 23a shows highly birefringent rhombic bipyramids, 
which are characterized by high stability upon air exposure and touch. Figures 23b and c 
show hexagonal prisms of low birefringence, which were stable upon touching, but lost 
their hexagonal outline and turned into drop-like entities after ~1min of air-exposure. 
Despite the difficulties with the latter crystals, both forms were used for soaking with 
P195-201.  
 
 
Figure 23: BDV Nucleoprotein crystals 
a) Bipyramid BDV N crystals. b) and c) hexagonal BDV N crystals from different perspectives. Crystals grew 
in 0.1M MES, 10% PEG 6000. 
 
Independent of the applied soaking method and crystal form, some of the crystals 
cracked and broke down upon peptide-dispersion in the drop. Others slowly (~1min) 
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dissolved. Nevertheless, a few of them (both forms) sustained the treatment and were 
analyzed on beamline ID 14-2 (ESRF, Grenoble) 3-7d after soaking. None of those 
crystals diffracted at all. Considering these results, it is most likely that the peptide 
bound to N within the crystal and thus disrupted the crystal lattice. This left so-called 
non-diffracting “phantom-crystals”. Such a phenomenon may happen without 
destroying the crystal outline. It should be noted that the rhombic bipyramid crystals 
without the peptide, usually diffracted to ~1.7 Å and displayed a very tight crystal 
packing. Furthermore their morphology was identical to those used to solve the initial 
structure of N (Rudolph et al., 2003). The peptide may have bound at the putative P-
interaction domain (amino acids 51-100) (Berg et al., 1998), involved in close crystal 
contacts with a neighbouring molecule and thus disrupted the crystal lattice. 
The hexagon prism crystals did not diffract independently of the presence of the 
peptide. 
A last attempt was made, trying to crystallize N-P' in a triple complex with BDV X. It has 
been shown earlier that BDV P interacts with X via amino acids 72-86 (Schwemmle et al., 
1998; Kobayashi et al., 2000; Schneider et al., 2004) (Figure 10). Furthermore, N, P and X 
were shown to form triple complexes, whereas P is the connector between N and X 
(Schwemmle et al., 1998). X may have had an additional stabilizing influence on P'. 
Figure 24 shows the last purification step of the triple complex via size-exclusion 
chromatography and the analysis by SDS-PAGE. The elution peak is at 12.98ml and 
shows a shoulder on the left, therefore fractions 10-12 were pooled and subjected to 
the crystallization robot at concentrations of 3 and 6mg/ml. No crystals appeared in any 
of the conditions and thus, no further crystallization attempts were made. 
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Figure 24: Purification of the BDV N-P-X triple complex 
a) Size-exclusion chromatography profile of N-P-X, displaying a shoulder left of the major peak. Fractions 
taken for analysis are depicted by black bars on the horizontal axis and green numbers. The blue line 
depicts the UV absorption per ml at 280nm, the red dashed line at 260nm. b) Analysis by 16% Tris-Tricine 
PAGE. Fractions 10-12 were taken for crystallisation. 
 
3.5  N-RNA AND N-P’-RNA INTERACTION 
Although RABV and VSV nucleoprotein expression in E. coli or insect cells induces the 
spontaneous uptake of cellular RNA, which results in the formation of N-RNA polymers 
(Spehner et al., 1991; Iseni et al., 1998; Schoehn et al., 2001; Mavrakis et al., 2002; 
Schoehn et al., 2004), such a phenomenon is not observed upon recombinant BDV N 
expression (Rudolph et al., 2003). I thus prepared BDV-genomic RNA fragments which 
derived from the 5’ and the 3’ termini (NCBI Nucleotide ID: AJ311522 Borna disease 
virus, strain He/80/FR, complete genome) (Figure 25) and incubated N and N-P’ 
complexes with a two molar excess of RNA alone or in combination with increasing 
concentrations of urea to aid in tetramer destabilization (Figure 26).  
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Figure 25: BDV 5’ Trailer and 3’Leader RNA 
a) BDV 5’ Trailer and 3’ Leader RNA after in vitro transcription and b) after purification, analyzed by 8% 
urea PAGE. Stain: Methylene blue 
 
Both N and N-P’ bands shift to a new position in a native gel when incubated with BDV-
genomic 5’-trailer RNA (125 nucleotides) in the absence of urea (Figure 26a, upper 
panel). In contrast, no gel shifts were observed when N and N-P’ were incubated with 
BDV genomic 3’-leader RNA (125 nucleotides) and total E.coli RNA (Figure 26a, lanes 1 
and 2).  
The efficiency of N-RNA and N-P’-RNA complex formation with 5’ genomic RNA 
improved with increasing urea concentrations, leading to the appearance of prominent 
new bands in both cases (Figure 26a, lanes 4, 5 and 6). Notably N and N-P’ incubation 
with 4 M urea did not change their mobility on a native gel indicating that the urea 
treatment did not affect the oligomerization or conformation of N and N-P complexes 
(Fig.26a, lane 7). Some complex formation was observed when N and N-P’ were 
incubated with 3’ genomic RNA or even E. coli RNA (of variable length) under 4M urea 
conditions, leading to the appearance of a ladder of new bands (Fig.25a lanes 6). To 
verify the presence of P’ in the N-P’-RNA complex, the bands corresponding to N-P’ and 
N-P’-RNA were excised from a native gel, the proteins eluted from the gel and separated 
on SDS-PAGE. This indicated that the N-P’ complex contained P’ as expected as well as 
the N-P’-RNA complex (Fig.26c). I then compared complex formation of 5’trailer RNA 
and 5’ antigenomic RNA with N using DIG labeled RNA. This indicated N interaction with 
the 5’antigenomic RNA in the presence and absence of urea (Figure 26b, lanes 2 and 3); 
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however the band shift produced by 5’ antigenomic RNA N-interaction are less compact 
than those produced by N interaction with 5’ trailer RNA (Figure 26b, lanes 5 and 6). 
 
 
Figure 26: N-RNA and N-P’-RNA gel shift experiments.   
a) BDV-N and BDV-N-P’ (left and right panel, respectively) incubated with a 2M excess of BDV-5’-Trailer- 
BDV-3’-Leader and total E. coli RNA (indicated as BDV-5’-Tr, BDV-3’-Ld- and tot. E. coli RNA, respectively) 
in presence of 0-4M Urea, subjected to 6.5% native PAGE. Asterisks mark prominent shift bands. b) Gel 
shift analysis of DIG-labeled 5’trailer RNA and 5’antigenomic RNA. The positions of free RNA and N-RNA 
complexes are indicated. c) Presence of P’ in RNA-shift bands. Bands corresponding to N-P’ (exN-P’) and N-
P’-RNA (exN-P’-RNA) were excised from a native gel and extracted from gel slices prior to separation on a 
16% SDS-PAGE together with a control of purified N-P’ complex. Faint bands at ~30 kDa may be a 
degradative product of N or contamination, resulting from band excision. Bands were visualized with 
Coomassie Brilliant Blue. Protein standards are indicated. 
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These results indicate that encapsidation of RNA by N is more efficient in the presence 
of 5’ genomic RNA. Since viral nucleoproteins need to recognize RNA in a non-sequence-
specific manner, the preference for 5’ genomic RNA might be explained by the 
formation of a hairpin structure adopted by the 5’ RNA segment that might specifically 
interact with N. Secondly, we show that N-RNA complexes are still able to bind to P as 
required for a functional N-RNA polymer present in a nucleocapsid. These results 
indicate that encapsidation of RNA by N is more efficient in the presence of 5’ genomic 
RNA. Since viral nucleoproteins need to recognize RNA in a sequence non-specific 
manner, the preference for 5’ genomic RNA could be explained by the formation of a 
hairpin structure adopted by the 5’ RNA segment that could specifically interact with N. 
Secondly, I could show that N-RNA complexes are still able to bind to P as required for a 
functional N-RNA polymer present in a nucleocapsid.  
 
3.6  ELECTRON MICROSCOPY OF N-RNA AND N-P’-RNA POLYMERS 
N and N-P’ were incubated with BDV genomic 5’-RNA and protein-RNA complexes were 
separated from RNA-free protein by glycerol gradient centrifugation producing a single 
band on native gel electrophoresis (Figure 27a Fractions 11 and 12 and 27b, Fractions 10 
and 11). Negatively stained electron microscopy images revealed open circular and rod-
like structures for N-RNA and N-P’-RNA complexes which were not distinguishable from 
the former (Figure 28a and c).  
 
Figure 27: Glycerol Gradient Purification of N-RNA and N-P’-RNA complexes 
a) Native PAGE analysis (6.5%) of BDV N-RNA and b) N-P’-RNA after glycerol gradient centrifugation. Input 
indicates the samples before purification. Fractions 11 and 12 from a) and 10 and 11 from b) were pooled, 
dialyzed into 20mM Hepes, pH 7.8, 20mM NaCl prior to EM analysis. 
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The circular polymers have an outer diameter of ~10-11 nm and the rods show a length 
of ~12-14 nm. The absence of the typical shape of N tetramers (Figure 28b) in the N-RNA 
complex images and the width of the N-RNA rods (35 ±4 Å) indicated that the tetramer 
(~59x59x87 Å), (Rudolph et al., 2003) disassembled; this led most likely to N protomers 
lining up along the RNA chain, as demonstrated for VSV and RABV N-RNA (Albertini et 
al., 2006; Green et al., 2006) (Figure 28c).  
 
 
Figure 28: Electron microscopy of N-RNA and N-P’-RNA polymers 
a) Negative staining electron microscopy of N in complex with RNA; open ring and rod-like structures can 
be observed for the protein-RNA complexes, which are highlighted by white rings and squares, 
respectively. b) Negative staining EM images of N-tetramers revealed smaller complexes (top view 
highlighted by white ring). c) and d) correspond to a) and b), showing N-P’-RNA and N-P’, respectively. The 
scale bar corresponds to all images. 
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3.7  BDV N SEQUESTERS RNA IN A CLEFT BETWEEN THE N-AND C-TERMINAL  
 DOMAINS 
The global structural similarity of BDV N and rhabdoviridae N (Albertini et al., 2006; 
Green et al., 2006) suggested that the cleft between the N- and C-terminal domains of N 
harbors the RNA interaction sites. In order to test this hypothesis, N mutants were 
generated and analyzed for their ability to form polymers in the presence of 5’ genomic 
RNA. All purified N mutants elute in monodisperse peaks from a gel filtration 
chromatography column and migrate as single bands on a native gel indicating that the 
mutations did not unfold N. These mutations of K164D, R165D, K242A and R297D were 
identified as critical contact points for the RNA, since single mutations and double 
mutations abrogated N-RNA complex formation as evidenced by native gel analysis 
(Figure 29a; lanes 1-6). A Glu161Ser mutation and the deletion of 24 C-terminal residues 
had no significant effect and produced band shifts on a native gel, indicating polymer 
formation (Figure 29a; lanes 7-10). Wild type N produces a band shift under the same 
conditions (Figure 29a; lanes 11, 12). Thus, residues K164, R165, K242 and R297 from 
both the N-terminal and the C-terminal domains are implicated in RNA coordination, 
indicating that a stretch of RNA could bind within the cleft made up by the N- and C-
terminal domains (Figure 29b). 
To test whether the RNA in complex with N or N-P’ is sequestered by N or partly 
exposed, the degradation of the RNA was analyzed. Glycerol gradient centrifugation 
purified N-RNA and N-P’-RNA complexes were incubated with increasing concentrations 
of RNase A, divided into equal volumes and subjected to denaturing and native PAGE. 
This revealed that the RNA was not protected in both BDV N- and N-P’-RNA complexes, 
indicated by the rapid degradation of RNA at low RNase A concentrations (Figure 30a). 
However, the positions of the protein bands did not change on the native gel (Figure 
30b); indicating that N can form stable polymers in the absence of RNA once the 
polymers have been formed. RNA degradation was further confirmed by analyzing N-
RNA and N-P’-RNA complexes formed with DIG-labeled BDV-5’-RNA (see 2.2.13) 
incubated with 0.05 µg/ml RNase A.  
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Figure 29: Mapping of the N-RNA interaction site.  
a) Gel mobility shift assay of BDV genomic 5’-RNA interaction with mutants of N (indicated at the top) on a 
6.5 % native acrylamide gel visualized by Coomassie brilliant blue. The asterisks indicate the shift bands 
obtained after incubation of the different N mutants with the BDV genomic 5’ RNA. b) Surface 
representation of BDV-N monomer structure. The surfaces of amino acids found to be essential for RNA-
interaction are colored in blue. The direction of the RNA interaction is marked by arrows. The surface 
representation was generated with Pymol 0.99.  
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Figure 30: RNA in the N-RNA complex is accessible for degradation.  
a) Glycerol gradient purified N-RNA and N-P’-RNA complexes were incubated with 0, 0.05, 0.1, 0.2  and 
0.5μg/ml RNase A for 15 min at 37°C (lanes 1-5 of each panel, respectively). Reactions were stopped with 
RNA Guard RNase inhibitor (GE Healthcare) prior to separation on a 16% denaturing Urea acrylamide gel 
stained with ethidium bromide; the RNA marker is indicated on the left. Separation of the RNase A treated 
complexes b) N-RNA (upper gel) and N-P’-RNA (Lower gel) on a 6.5% native PAGE stained with Coomassie 
Brilliant Blue s. The positions of N and N-P’ complexes are shown as controls in lane 1, respectively. c) 
RNase protection assay with DIG labeled BDV-5’-Trailer-RNA. RNA mixed with N and N-P’ was incubated 
with 0, 0.05, 0.1 and 0.2 μg/ml RNase A. (-) corresponds to untreated RNA, (+) to RNA treated with RNase 
A at a concentration of 0.05 μg/ml. Samples were separated by 15% denaturing Urea PAGE and electro- 
blotted on a Nylon membrane. RNA was detected by AP-coupled anti-DIG-Fab fragments (Roche). Black 
bars indicate increasing RNAse A concentrations per lane. Asterisks mark the two bands of protected RNA 
fragments. 
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The higher sensitivity of this assay revealed the appearance of two small RNA bands 
upon RNase A treatment of RNA alone, N-RNA and N-P’-RNA complexes (Figure 30c). 
Although we could not determine the size of the small RNAs, the bands could represent 
the 5’ RNA region that is thought to adopt a hairpin structure; it is thus most likely that 
this region is not directly incorporated into the nucleoprotein RNA interaction cleft. The 
presence of a specific tertiary RNA structure within the 5’ genomic RNA is further 
supported by the fact that the same small RNA fragments are produced upon RNase A 
treatment of the RNA alone (Figure 30c). 
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4  Discussion 
4.1  N-P’ Crystallization attempts 
They may act in nuclear trafficking and maintenance of a favourable N-to-P ratio in the 
nucleus, required for efficient replication and transcription (Schneider et al., 2003; 
Schneider et al., 2004; Schneider, 2005).  
A crystal structure would have provided exact structural information about N-P 
interaction properties, such as amino acids involved in interaction; the P binding site on 
N and interaction-induced conformational changes on N. 
However, none of the attempts to obtain a structure of BDV N with any P-derived 
peptide has been successful. Nevertheless, the crystal morphologies and the 
crystallization conditions differed, dependent if BDV N alone or in complex with a P-
peptide were present in the setup (Figure 18a and 23a). This indicates that the P-
peptides dissociated from N and induced faster nucleation, thus generating low-quality 
N-crystals. Another explanation is that the P-peptides did not dissociate, but degraded 
and hence could not be detected by molecular replacement due to the poor crystal 
quality. Crystals growing in drops containing N only (Figure 23a), belonged to the 
tetragonal space group I4, with unit cell dimensions of a=100Å and c=103.2Å, identical 
with those used to solve the initial structure by (Rudolph et al., 2003); the N- and C-
terminal domains of the nucleoprotein tetramers were facing away from each other in 
the crystal lattice and the putative P-binding site (aa 56-100) (Berg et al., 1998) was 
involved in crystal contacts with a neighbouring tetramer. Crystals growing in drops 
containing N-P’ however (Figure 18b and c), belonged to the monoclinic space group C2, 
with unit cell dimensions of a=274Å, b=81Å and c=81,5Å (Table 6). Each N tetramer was 
positioned face-to-face with another one and the putative P binding region was not 
involved in crystal contacts, theoretically leaving space for a bound P-peptide. These 
data indicate that a P-peptide may have co-crystallised with N in the respective 
conditions. Presence of such a peptide in the crystal remains to be proved though, 
because crystal analysis by SDS-PAGE was never conclusive. In addition, the N structure 
obtained from the C2 crystals is not complete, especially around the putative P-binding 
region, which does not allow precise conclusions. 
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Thus, better methods need to be employed to verify P-peptide presence within those 
crystals and further crystal improvement should be considered in case of proof. 
 
 
4.2  N-RNA AND N-P’-RNA INTERACTION 
Nucleoproteins from negative strand RNA viruses such as VSV and RABV encapsidate 
their RNA genome and protect it from the hostile environment in the host cell. The 
interaction of N with RNA induces polymerization of N along the RNA genome and each 
protomer interacts with a short stretch of RNA in a non-sequence specific manner. This 
has been demonstrated by the crystal structures of N-RNA rings from recombinantly 
expressed nucleoproteins, bound to cellular RNA (Albertini et al., 2006; Green et al., 
2006) (Figure 31b and c). Polymerization is achieved by short N- and C-terminal 
extensions, involved in domain exchange (Figure 31b and c). A similar mode has been 
proposed for influenza N, although only one flexible tail loop accounts for trimerization 
or polymerization respectively (Figure 31a and b) (Ye et al., 2006; Coloma et al., 2009). 
The RNA in the RABV and VSV rings is entirely occluded within a predominantly basic 
cleft, formed by helical N- and C-terminal domains of each N protomer (Figure 31 b and 
c). Likewise, the influenza virus nucleoprotein, exhibits such a basically charged cleft 
proposed to constitute the RNA binding site.(Ye et al., 2006; Albertini et al., 2008; 
Coloma et al., 2009) (Figure 31b).  
The overall structural similarity of BDV N and VSV or RABV N suggested that BDV N 
might coordinate RNA in a similar manner (Figure 31a) (Albertini et al., 2006; Green et 
al., 2006; Albertini et al., 2008). 
I thus employed an assay that permitted destabilization of the N tetramers, which led to 
the formation of N-RNA polymers in vitro.  
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Figure 31: Comparison of known viral nucleoprotein structures in polymeric and monomeric states. 
a) Ribbon diagram of the BDV nucleoprotein in its unliganded form. The upper panel shows the tetrameric 
form found in solution and in the crystal; lower panel shows the monomer composed of two main 
domains and two small extra domains emanating from the N- and C-terminal domains and involved in 
domain exchange in the tetramer structure. The putative RNA binding site in the monomer is indicated by 
an arrow. b) Ribbon diagram of the influenza virus nucleoprotein in its RNA-free conformation. The upper 
panel shows the trimer found in solution and in the crystal. The lower panel shows the monomer 
composed of two helical domains whose arrangement generates a cleft, which was proposed to constitute 
the RNA binding site (arrow). A flexible tail loop extends from the C-terminal domain is implicated in 
trimerisation and polymerization. c) Ribbon diagram of the rabies virus N-RNA complex; upper panel 
shows the two 11-mer NRNA ring complexes contained in the crystal asymmetric unit; lower panel shows 
the monomer in complex with RNA. d) Ribbon diagram of the VSV N-RNA complex; upper panel shows the 
recombinant 10 mer N-RNA ring complex; lower panel shows the monomer in complex with RNA. 
Figure was adopted and modified from (Albertini et al., 2008). Ribbon diagrams were generated with 
Pymol 0.99. PDB IDs: BDV-N, 1PPT; Influenza virus N, 2IQH; Rabies virus N-RNA, 2GTT; VSV N-RNA, 2GIC.  
  
DISCUSSION 
 
80 
 
One dimension of the polymers, their width, resemble that of nucleocapsids present in 
BDV (Figure 1c, see 1.2.1 and 3.5) (Kohno et al., 1999). Mutagenesis of basic residues 
within the cleft made up by the N- and C-terminal domains confirmed this region as 
major RNA binding site. This is in contrast to previous assumptions that the RNA might 
run through the basically charged channel (Figure 32a and b) in the middle of the 
tetramer or a basic cleft, running diagonally across the tetramer (Figure 32c) (Rudolph et 
al., 2003).  
 
 
Figure 32: Surface Potential Representation of the BDV-N Tetramer  
a) Electrostatic potential distribution of N. The view is on the N-terminal domains, showing the entrance 
to the positively charged channel. Areas coloured in white, red, and blue denote neutral, negative, and 
positive potential, respectively. b) Bottom view of a) rotated 180° around the y-axis. The channel is 
negatively charged at this end. c) Side-view of a) rotated by 90° around the horizontal axis. A deep groove 
of positive surface potential runs diagonally across the side of the tetramer and marks the other assumed 
RNA binding site. d) Slab through the central channel showing the large cavity and the positively charged 
side channels normal to the central channel that lead to the surface of the tetramer. The backbone trace 
of the BDV-N is shown as a cyan ribbon. Figures were taken from (Rudolph et al., 2003). 
 
The bound RNA was sensitive to enzymatic RNA degradation suggesting that it is 
exposed in the N-RNA complex. This is in contrast to previous reports that showed that 
isolated BDV virus particles and RNPs are resistant against RNA degradation (Richt et al., 
1993; Cubitt &  de la Torre, 1994). In the first case, BDV-infected cells were treated with 
Freon-113, liberating BDV which was still infectious. This means that RNase A treatment 
was applied on intact BDV virions. The in-vitro conditions applied here for N-RNA 
DISCUSSION 
 
81 
 
assembly are thus not comparable to those conditions of ancient work. The difference 
might be due to the presence of other viral proteins such as G and probably the lipid 
envelope. Furthermore this may be because of the fact that the strings of N-RNA 
complexes might be packaged tighter in the nucleocapsid due to M that interacts with 
RNA and potentially with N (Mayer et al., 2005; Chase et al., 2007; Neumann et al., 
2009) or due to the presence of full length P in the wild type RNPs. However, it cannot 
be excluded that the usage of different RNases might have affected the outcome. BDV 
RNPs were protected from degradation by Micrococcus nuclease, but had not been 
tested for RNase A degradation before (Cubitt &  de la Torre, 1994). This is consistent 
with RNA protection observed in case of N-RNA complexes from RABV, whereas RNA 
present in nucleocapsids was entirely protected from micrococcal nuclease degradation, 
albeit RNase A treatment produced small RNA fragments of 4-9 nucleotides (Iseni et al., 
1998; Albertini et al., 2006). Sensitivity to RNase degradation was further reported for 
RNA within influenza virus RNPs (Duesberg, 1969; Kingsbury &  Webster, 1969; Baudin et 
al., 1994) similar to my results. Another explanation is that the RNA is not fully coated 
along its entire length by N, thus leaving portions of the phosphate backbone exposed to 
nuclease attack. There may also be regions of RNA that are looped out within and 
between adjacent nucleoprotein. 
A requirement for RNA protection might depend on the replication site within the cell. 
Both influenza and Borna disease viruses replicate in the nucleus, protected from the 
RNA degradation machinery. Other factors such as viral matrix proteins interacting with 
RNA themselves (Gomis-Rüth et al., 2003; Money et al., 2009; Neumann et al., 2009) or 
the formation of a compact structure of the RNPs might protect them during the 
transport in the cytosol to the sites of virus assembly. In contrast viruses such as RABV 
and VSV might have to protect their genomes better since they replicate in the cytosol. 
BDV N alone or in complex with P’ formed preferentially complexes with 5’ genomic 
RNA, indicating that N has the capacity to discriminate between RNA sequences, which 
is important for the specific encapsidation of genomic RNA during the replication cycle. 
This is consistent with previous studies on RABV, suggesting that the 5’ leader RNA plays 
an important role in conferring specific RNA encapsidation (Blumberg et al., 1983; 
Kouznetzoff et al., 1998). This process can be further modulated by P (Yang et al., 1998) 
and by phosphorylation of N (Toriumi &  Kawai, 2004). The in vitro degradation of a 5’ 
DISCUSSION 
 
82 
 
genomic RNA fragment revealed that two small regions are protected from complete 
degradation by RNase A, independent of the presence of N or N-P’. This suggests that 
part of the 5’ genomic RNA used in the study adopts a secondary or tertiary structure 
that is insensitive to RNase A degradation. This may be most likely due to the extreme 5’ 
end. Such a defined RNA structure could be recognized by N and thus serve as a starting 
signal to encapsidate RNA in a sequence unspecific manner as observed for RABV and 
VSV N-RNA interactions. Furthermore, RNA recognition by the N tetramer might help to 
destabilize the tetramer thus exposing the RNA binding sites. This hypothesis is 
supported by the fact that N tetramers do not interact with 3’ genomic RNA or E. coli 
RNA in the absence of urea as a destabilizing agent. Even in the presence of urea, 
neither N nor N-P tetramers are efficiently destabilized by 3’ genomic RNA or by E. coli 
RNA when compared to the effect of 5’ genomic RNA and to some extend of the 5’anti-
genomic RNA. Since the 3’ end of the genome is complementary to the 5’ region, it 
would be expected that the 5’ antigenome might adopt a similar conformation that 
permits N interaction, as we observe in the current study.  
The EM images of N-RNA and N-P’-RNA complexes do not reveal closed ring-like 
structures as observed for other negative strand RNA viruses (Iseni et al., 1998; Schoehn 
et al., 2001; Maclellan et al., 2007; Cox et al., 2009). This is most likely due to the 
presence of the 5’ end of the RNA genome that might adopt a defined structure that 
itself is not incorporated into the RNA binding cleft or may interact with native M 
protein. My data also suggest that the N tetramers have to disassemble upon RNA 
interaction. Firstly, the appearances of the EM images suggest the absence of N 
tetramers as building blocks of the polymers. Secondly, important basic residues 
required for RNA binding were mapped to the cleft that itself is sequestered in the 
interior of the N tetramer (Rudolph et al., 2003).  
Depletion of the RNA from the N-RNA and N-P’-RNA polymers indicate that 
polymerization is mainly stabilized via N-N protein interactions as shown for empty VSV 
ring-like nucleocapsids (Zhang et al., 2008). This suggests that polymerization is also 
most likely supported by domain exchange between protomers within the polymer 
similar to RABV and VSV N-RNA polymerization (Albertini et al., 2006; Green et al., 
2006).  
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The N-RNA complex constitutes the target for the polymerase complex composed of L 
and the phosphoprotein P. P regulates transcription and replication by linking the N-RNA 
complex to L (Schneider et al., 2004). Although it has been speculated that P forms 
dimers, trimers or tetramers based on gel filtration results (Schneider et al., 2004; 
Schneider, 2005) my analysis clearly shows that P forms tetramers in solution similar to 
P from Sendai virus (Tarbouriech et al., 2000). A similar oligomerization motif was 
predicted for BDV P (Schneider et al., 2004; Schneider, 2005). Although Cys 125 of BDV-P 
was implicated previously in disulfide cross-linked dimerization (Kliche et al., 1996) 
MALLs analysis of N-P complexes produced the same results in a reducing buffer (data 
not shown), indicating that Cys crosslinking is not required for oligomerization. My 
results suggest further that tetramer formation of P does not depend on 
phosphorylation as shown for Ps from Rhabdoviruses (Gigant et al., 2000; Gerard et al., 
2007). 
I could further show that P interaction with N requires a short C-terminal region of P 
including the last seven amino acids. This region binds N with a micromolar affinity 
similar to other N-P interactions; the C-terminal nucleocapsid-binding domain of 
measles virus P binds the nucleoprotein NTAIL peptide with an affinity constant of 13μM 
(Kingston et al., 2004) and the Sendai virus NTAIL-PX interaction has an affinity of ~57 μM 
(Houben et al., 2007). A low binding affinity is consistent with a model proposed for 
Sendai virus, whereas P is “cart wheeling” along the N-RNA during RNA-synthesis, by 
employing on-and-off interactions (Kolakofsky et al., 2004). 
Therefore a weak binding affinity between P and N proteins is energetically beneficial 
for movement of the L protein along the nucleocapsid. Since P proteins from negative 
strand RNA viruses adopt a modular structure (Karlin et al., 2003; Gerard et al., 2009) 
whereas the single domains are flexibly linked, BVD P might be similarly organized by 
utilizing a C-terminal domain for interaction with N tetramers as well as N-RNA 
polymers. The short N interaction site might further ensure that multiple Ps can 
simultaneously interact with at least four Ns while being linked to the polymerase L 
during replication and transcription. In summary our study provides a first model of the 
RNA interaction mode of BDV N and suggests that such N-RNA polymers could be targets 
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for low affinity interaction with tetrameric P and thus provide a link to the polymerase L 
during replication and transcription. 
.
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5  CONCLUSIONS  
 P’ oligomerizes into tetramers in solution.  
 
 N and P’ assemble into hetero-octamers with four P’ bound to the N-tetramer. 
 
  N-P’ interaction requires the last five C-terminal P residues to form a stable 
complex with a KD of 1.66 μM, consistent with an on-and-off interaction mode, 
which would theoretically allow the phosphoprotein to move along the 
nucleocapsid during replication and transcription. 
 
 The BDV N tetramer is destabilized upon formation of N-RNA complexes and 
polymerizes along the RNA chain as shown for N proteins of other MNVs. N-RNA 
assembles into open circular and rod-like structures, with the RNA exposed and 
accessible for degradation 
 
 BDV N interacts specifically with BDV specific genomic and antigenomic 5’ RNA, 
but not with genomic 3’ RNA or total E. coli RNA. 
 
 N-RNA polymers are formed in the presence of P’ leading to P’-N-RNA 
polymers. 
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7  Abbreviations 
 
Aminoacids 
A Ala  Alanin 
C Cys  Cystein 
D Asp  Aspartat 
E Glu  Glutamat 
F Phe  Phenylalanin 
G Gly  Glycin 
H His  Histidin 
I Ile  Isoleucin 
K Lys  Lysin 
L Leu  Leucin 
M Met  Methionin 
N Asn  Asparagin 
P Pro  Prolin 
Q Gln  Glutamin 
R Arg  Arginin 
S Ser  Serin 
T Thr  Threonin 
V Val  Valin 
W Trp  Tryptophan 
Y Tyr  Tyrosin 
 
Viral Proteins 
G  Glycoprotein 
L  Viral polymerase 
M  Matrixprotein 
N   Nucleoprotein 
P  Phosphoprotein  
P’  N-terminal truncated isoform of BDV P 
X  BDV X protein 
 
General 
aa    Aminoacid 
ATP    Adenosine triphosphate 
bp    Base pairs 
BDV    Borna Disease virus  
CNS    Central nervous system  
C-terminal   Carboxy-terminal 
CTP    Cytosine triphosphate 
Da    Dalton  
DNA    Deoxyribonucleic acid 
dNTP    Deoxynucleosid triphosphate 
E. coli    Escherichia coli 
et al.    et aliter (and others) 
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GTP    Guanosin triphosphate 
His-Tag   Affinity tag, consisting of 6 Histidines 
MCS    Multiple cloning site 
MNV    Mononegavirales 
NNS RNA virus   non-segmented negative-sense single-strand RNA virus 
N-terminal   Amino-terminal 
OD    Optical density 
ORF    Open reading frame 
PAGE    Polyacrylamide gelelectrophoresis 
Pi    Isoelectric point 
RABV    Rhabies virus 
RNA    Ribonucleic acid 
UTP    Uridin triphosphate 
VSV    Vesicular stomatitis virus  
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